Michael Rod Zalutsky | Scholars@Duke

Michael Rod Zalutsky
Jonathan Spicehandler, M.D. Distinguished Professor of Neuro Oncology, in the School of Medicine

The overall objective of our laboratory is the development of novel radioactive compounds for improving the diagnosis and treatment of cancer. This work primarily involves radiohalo-genation of biomolecules via site-specific approaches, generally via demetallation reactions. Radionuclides utilized for imaging include I-123, I-124 and F-18, the later two being of particular interest because they can be used for the quantification of biochemical and physiological processes in the living human through positron emission tomography. For therapy, astatine-211 decays by the emission of alpha-particles, a type of radiation considerably more cytotoxic that the beta-particles used in conventional endoradiotherapy. The range of At-211 alpha particles is only a few cell diameters, offering the possibility of extremely focal irradiation of malignant cells while leaving neighboring cells intact. Highlights of recent work include: a)
development of reagents for protein and peptide radioiodination that decrease deiodination in vivo by up to 100-fold, b) demonstration that At-211 labeled monoclonal antibodies are effective in the treatment of a rat model of neoplastic meningitis, c) synthesis of a thymidine analogue labeled with At-211 and the demonstration that this molecule is taken up in cellular DNA with highly cytotoxicity even at levels of only one atom bound per cell and d) development of
radiohalobenzylguanidines which are specifically cytotoxic for human neuroblastoma cells.

Current Appointments & Affiliations

Jonathan Spicehandler, M.D. Distinguished Professor of Neuro Oncology, in the School of Medicine, Radiology, Clinical Science Departments 2008
Professor of Radiology, Radiology, Clinical Science Departments 2018
Professor of Radiation Oncology, Radiation Oncology, Clinical Science Departments 2009
Professor in Pathology, Pathology, Clinical Science Departments 2017
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1985

Contact Information

311 Research Drive, 161H Bryan Res Bldg, Durham, NC 27710
Box 3808 Med Ctr, Durham, NC 27710
zalut001@mc.duke.edu (919) 684-7708
Google Scholar

Background
Education, Training, & Certifications
- Ph.D., Washington University in St. Louis 1974
- M.A., Washington University in St. Louis 1972
Duke Appointment History
- Professor of Radiology, Radiology, Clinical Science Departments 1990 - 2018
- Associate Professor in Pathology, Pathology, Clinical Science Departments 1998 - 2017
- Assistant Professor in Pathology, Pathology, Clinical Science Departments 1994 - 1998
Recognition
Awards & Honors
- Aebersold Award. Socienty of Nuclear Medicine. 2007
- MERIT Award. National Institutes of Health. 2005
Research
Selected Grants
- Evaluating the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM Treatment awarded by Northwestern University 2021 - 2022
- CA181292 Targeted Gold Nanoparticles (AuNPs) for Potent Alpha-Particle Radiotherapy of Brain Cancer awarded by United States Army Medical Research Acquisition Activity 2019 - 2022
- Flourine-18 labeled MDM2 antagonists for PET imaging awarded by National Institutes of Health 2020 - 2022
- Small Molecule PSMA-Targeted Alpha Therapy awarded by Johns Hopkins University 2014 - 2022
- Astatine And Iodine Radiolabeled Monoclonal Antibodies awarded by National Institutes of Health 1985 - 2021
- Enhancing Radionuclide Production Capabilities at the Duke University Medical Center Cyclotron with a Focus on Astatine-211 awarded by Department of Energy 2019 - 2021
- Image-guided Dosimetry for Injectable Brachytherapy based on Elastin-like Polypeptide Nanoparticles awarded by National Institutes of Health 2017 - 2021
- Labeling nanobodies with 18F residualizing labels for HER2 specific PET imaging awarded by National Institutes of Health 2015 - 2021
- Development of Tethered Hsp90 Inhibitors Carrying Radioiodinated Probes to Specifically Descriminate and Kill Malignant Breast Tumor Cells awarded by Department of Defense 2015 - 2019
- Development of Tethered Hsp90 Inhibitors Carrying Radioiodinated Probes to Specifically Discriminate and Kill Malignant Breast Tumor Cells awarded by Department of Defense 2015 - 2019
- Systemically administrered EGRFvIII-targeted bispecific antibody as an immunotherapeutic for glioblastoma. awarded by National Institutes of Health 2015 - 2019
- Novel Radiohalogenation Strategies for Enhancing Imaging and Targeted Radiotherapy with Ultrasmall Dual- Modality Silica Nanoparticles (C Dots) awarded by Memorial Sloan-Kettering Cancer Center 2016 - 2018
- Treating Melanoma with a Molecularly Engineered, Long Circulating Immunotoxin awarded by National Institutes of Health 2015 - 2018
- Development of a Targeted Radionuclide Therapy for Triple Negative Breast Cancer awarded by OncoTAb, Inc. 2016 - 2017
- Pediatric Brain Tumor Consortium awarded by St. Jude Children's Research Hospital 2014 - 2017
- Imaging IDH1 Mutations in Glioma and Other Malignancies awarded by National Institutes of Health 2014 - 2016
- Research Training In Neuro-Oncology awarded by National Institutes of Health 1998 - 2016
- Thermally Triggered Multivalent Targeting of Tumors awarded by National Institutes of Health 2007 - 2016
- Thermally Targeted Drug Delivery by Elastin Biopolymers awarded by National Institutes of Health 2002 - 2016
- Local Radionuclide Delivery to Solid Tumors by Injectible Biopolymer awarded by National Institutes of Health 2009 - 2016
- Production of Astatine-211 at the Duke University Medical Center for its Regional Distribution in support of Biomedical Research awarded by Department of Energy 2012 - 2014
- Modulation of the blood-tumor barrier through targeted suppression of claudin 5 awarded by National Institutes of Health 2011 - 2013
- Cross-disciplinary Training in Medical Physics awarded by National Institutes of Health 2007 - 2013
- Brain Tumors - Immunological and Biological Studies awarded by National Institutes of Health 2001 - 2013
- Small Animal PET / CT Molecular Imaging awarded by National Institutes of Health 2011 - 2012
- Radionuclide-based Molecular Imaging of the DNA Repair Protein AGT awarded by National Institutes of Health 2009 - 2011
- Astatine-211 Radiochemistry: The Development of Methodologies for High Activity Level Radio-Synthesis awarded by Department of Energy 2008 - 2010
- Research Training In Neuro-Oncology awarded by National Institutes of Health 2005 - 2010
- Thermally-Induced Intra-Articular Drug Delivery System awarded by National Institutes of Health 2006 - 2009
- Imaging of O6-Alkylguianine-DNA Alkyltransferase awarded by National Institutes of Health 2002 - 2007
- Targeted Radiotherapeutics: Chemical and Biological Aspects awarded by Department of Energy 2004 - 2006
- Astatine-211 & Radioiodine Labeled Octreotide Conjugates awarded by National Institutes of Health 2001 - 2006
- Anti-Tenascin Antibody Constructs awarded by Department of Energy 1995 - 2005
- GCRC CAP awarded by National Institutes of Health 2000 - 2005
- Higher Oxidation State Astatine-211 Radiopharmaceuticals awarded by National Institutes of Health 2003 - 2005
- Molecular Imaging Center Planning Grant awarded by National Institutes of Health 2000 - 2004
- Astatine And Iodine Radiolabeled Monoclonal Antibodies awarded by National Institutes of Health 1999 - 2004
- Development of Novel Tumor Imaging Agents awarded by National Institutes of Health 2000 - 2003
- Radiolabeled Monoclonal Antibodies And Hyperthermia awarded by Department of Energy 1998 - 2001
- Brain Tumors--Immunological and Biological Studies awarded by National Institutes of Health 1976 - 2001
- Brain Tumors - Immunological And Biological Studies awarded by National Institutes of Health 1997 - 1999
- Src On Primary And Matastatic Tumors Of The Cns awarded by National Institutes of Health 1994 - 1999
- Astatine And Iodine Radiolabeled Monoclonal Antibodies awarded by National Institutes of Health 1994 - 1999
- Src On Primary And Metastatic Tumors Of The Cns awarded by National Institutes of Health 1997 - 1999
- Astatine And Iodine Radiolabeled Monoclonal Antibodies awarded by National Institutes of Health 1993 - 1999
- Astatine And Iodine Radiolabeled Monoclonal Antibodies awarded by National Institutes of Health 1985 - 1999
- Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Positron Emission Imaging Of Tumors Using Monoclonal Antib awarded by Department of Energy 1995 - 1998
- Mibg And Analogs For Diagnosis And Therapy awarded by National Institutes of Health 1993 - 1998
- Recombinant Anti-Tenascin Antibody Constructs awarded by Department of Energy 1995 - 1998
- Positron Tomographic Imaging Of Tumors Using Monoclonal An awarded by Department of Energy 1993 - 1995
- Positron Emission Tomography Imaging Of Tumors Using Monoc awarded by Department of Energy 1992 - 1995
- Intrathecal Therapy Of Melanoma Neoplastic Meningitis awarded by National Institutes of Health 1993 - 1995
- Positron Emission Tom0graphic Imaging Of Tumors Using Mono awarded by Department of Energy 1992 - 1995
- Positron Emission Tomographic Imaging Of Tumors Using Mono awarded by Department of Energy 1989 - 1995
- Specific Applications Of Pet And Mrs In Brain Tumors awarded by National Institutes of Health 1994 - 1995
- Scor In Coronary And Vascular Diseases awarded by National Institutes of Health 1992 - 1994
- Src On Malignant Human Gliomas And Medulloblastomas awarded by National Institutes of Health 1993 - 1994
- Cancer And Leukemia Group B Statistical Center awarded by National Institutes of Health 1992 - 1993
- Positron Emission Tomagraphic Imaging Of Tumors Using Mono awarded by Department of Energy 1991 - 1992
- Positron Emission Tomagraphic Imaging Of Tumors Using ... awarded by Department of Education 1990 - 1992
- Positron Emission Tomogrphic Imaging Of Tumors Using Monoc awarded by Department of Energy 1989 - 1992
- Radiotherapy Using Monoclonal Antibodies And Astatine awarded by National Institutes of Health 1987 - 1989
External Relationships
- Zentalis (was called Zeno)
- cereius
- precision molecular, inc
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Zhou, Zhengyuan, Michael R. Zalutsky, and Satish K. Chitneni. “Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.” Mol Pharm 18, no. 10 (October 4, 2021): 3871–81. https://doi.org/10.1021/acs.molpharmaceut.1c00531.
    Full Text Open Access Copy Link to Item
  - Feng, Yutian, and Michael R. Zalutsky. “Production, purification and availability of 211At: Near term steps towards global access.” Nucl Med Biol 100–101 (September 2021): 12–23. https://doi.org/10.1016/j.nucmedbio.2021.05.007.
    Full Text Link to Item
  - Zhou, Zhengyuan, Darryl McDougald, Rebecca Meshaw, Irina Balyasnikova, Michael R. Zalutsky, and Ganesan Vaidyanathan. “Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate.” Nucl Med Biol 100–101 (September 2021): 24–35. https://doi.org/10.1016/j.nucmedbio.2021.06.002.
    Full Text Link to Item
  - Chitneni, Satish K., Zhengyuan Zhou, Brian E. Watts, and Michael R. Zalutsky. “Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141.” Pharmaceuticals (Basel) 14, no. 4 (April 13, 2021). https://doi.org/10.3390/ph14040358.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Ronnie C. Mease, Il Minn, Jaeyeon Choi, Ying Chen, Hassan Shallal, Choong Mo Kang, et al. “Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.” Nucl Med Biol 94–95 (March 2021): 67–80. https://doi.org/10.1016/j.nucmedbio.2021.01.002.
    Full Text Link to Item
  - Zhou, Zhengyuan, Rebecca Meshaw, Michael R. Zalutsky, and Ganesan Vaidyanathan. “Site-Specific and Residualizing Linker for 18F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.” J Nucl Med, February 26, 2021. https://doi.org/10.2967/jnumed.120.261446.
    Full Text Link to Item
  - Feng, Yutian, Zhengyuan Zhou, Darryl McDougald, Rebecca L. Meshaw, Ganesan Vaidyanathan, and Michael R. Zalutsky. “Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.” Nuclear Medicine and Biology 92 (January 2021): 171–83. https://doi.org/10.1016/j.nucmedbio.2020.05.002.
    Full Text
  - Babak, Maria V., Michael R. Zalutsky, and Irina V. Balyasnikova. “Heterogeneity and vascular permeability of breast cancer brain metastases.” Cancer Lett 489 (October 1, 2020): 174–81. https://doi.org/10.1016/j.canlet.2020.06.012.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Oscar R. Pozzi, Jaeyeon Choi, Xiao-Guang Zhao, Shawn Murphy, and Michael R. Zalutsky. “Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor.” Cancer Biother Radiopharm 35, no. 7 (September 2020): 511–19. https://doi.org/10.1089/cbr.2019.3204.
    Full Text Link to Item
  - Zhou, Zhengyuan, Michael R. Zalutsky, and Ganesan Vaidyanathan. “Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative.” Bioorg Med Chem 28, no. 17 (September 1, 2020): 115634. https://doi.org/10.1016/j.bmc.2020.115634.
    Full Text Link to Item
  - Jannetti, Stephen A., Brian M. Zeglis, Michael R. Zalutsky, and Thomas Reiner. “Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy.” Front Pharmacol 11 (2020): 170. https://doi.org/10.3389/fphar.2020.00170.
    Full Text Link to Item
  - Rosenkranz, Andrey A., Tatiana A. Slastnikova, Georgii P. Georgiev, Michael R. Zalutsky, and Alexander S. Sobolev. “Delivery systems exploiting natural cell transport processes of macromolecules for intracellular targeting of Auger electron emitters.” Nucl Med Biol 80–81 (January 2020): 45–56. https://doi.org/10.1016/j.nucmedbio.2019.11.005.
    Full Text Link to Item
  - Chitneni, Satish K., Eftychia Koumarianou, Ganesan Vaidyanathan, and Michael R. Zalutsky. “Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab.” Molecules 24, no. 21 (October 30, 2019): 3907–3907. https://doi.org/10.3390/molecules24213907.
    Full Text
  - Liu, Yang, Austin B. Carpenter, Christopher J. Pirozzi, Hsiangkuo Yuan, Matthew S. Waitkus, Zhengyuan Zhou, Landon Hansen, et al. “Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe.” Nanotechnology 30, no. 27 (July 5, 2019): 275101. https://doi.org/10.1088/1361-6528/ab0e9c.
    Full Text Link to Item
  - Zhou, Zhengyuan, Darryl McDougald, Nick Devoogdt, Michael R. Zalutsky, and Ganesan Vaidyanathan. “Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios.” Mol Pharm 16, no. 1 (January 7, 2019): 214–26. https://doi.org/10.1021/acs.molpharmaceut.8b00951.
    Full Text Link to Item
  - Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R. Zalutsky, Charles Spritzer, et al. “Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.” Plos One 14, no. 5 (2019): e0216934. https://doi.org/10.1371/journal.pone.0216934.
    Full Text Link to Item
  - Zhou, Zhengyuan, Nick Devoogdt, Michael R. Zalutsky, and Ganesan Vaidyanathan. “An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker.” Bioconjug Chem 29, no. 12 (December 19, 2018): 4090–4103. https://doi.org/10.1021/acs.bioconjchem.8b00699.
    Full Text Link to Item
  - Chitneni, Satish K., Hai Yan, and Michael R. Zalutsky. “Synthesis and Evaluation of a 18F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET.” Acs Med Chem Lett 9, no. 7 (July 12, 2018): 606–11. https://doi.org/10.1021/acsmedchemlett.7b00478.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Choong Mo Kang, Darryl McDougald, Il Minn, Mary Brummet, Martin G. Pomper, and Michael R. Zalutsky. “Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.” Nucl Med Biol 62–63 (July 2018): 18–30. https://doi.org/10.1016/j.nucmedbio.2018.05.002.
    Full Text Link to Item
  - Pruszynski, Marek, Choong Mo Kang, Eftychia Koumarianou, Ganesan Vaidyanathan, and Michael R. Zalutsky. “d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution.” Molecules 23, no. 5 (May 20, 2018). https://doi.org/10.3390/molecules23051223.
    Full Text Link to Item
  - Zhou, Zhengyuan, Satish K. Chitneni, Nick Devoogdt, Michael R. Zalutsky, and Ganesan Vaidyanathan. “Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.” Bioorg Med Chem 26, no. 8 (May 1, 2018): 1939–49. https://doi.org/10.1016/j.bmc.2018.02.040.
    Full Text Link to Item
  - Chitneni, Satish K., Zachary J. Reitman, Rebecca Spicehandler, David M. Gooden, Hai Yan, and Michael R. Zalutsky. “Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.” Bioorg Med Chem Lett 28, no. 4 (February 15, 2018): 694–99. https://doi.org/10.1016/j.bmcl.2018.01.015.
    Full Text Link to Item
  - Choi, Jaeyeon, Ganesan Vaidyanathan, Eftychia Koumarianou, Choong Mo Kang, and Michael R. Zalutsky. “Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.” Nucl Med Biol 56 (January 2018): 10–20. https://doi.org/10.1016/j.nucmedbio.2017.09.003.
    Full Text Open Access Copy Link to Item
  - Zhou, Zhengyuan, Ganesan Vaidyanathan, Darryl McDougald, Choong Mo Kang, Irina Balyasnikova, Nick Devoogdt, Angeline N. Ta, Brian R. McNaughton, and Michael R. Zalutsky. “Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.” Mol Imaging Biol 19, no. 6 (December 2017): 867–77. https://doi.org/10.1007/s11307-017-1082-x.
    Full Text Link to Item
  - D’Huyvetter, Matthias, Jens De Vos, Catarina Xavier, Marek Pruszynski, Yann G. J. Sterckx, Sam Massa, Geert Raes, et al. “131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment.” Clin Cancer Res 23, no. 21 (November 1, 2017): 6616–28. https://doi.org/10.1158/1078-0432.CCR-17-0310.
    Full Text Link to Item
  - Raghavan, Raghu, Roger W. Howell, and Michael R. Zalutsky. “A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.” Biomed Phys Eng Express 3, no. 3 (June 2017). https://doi.org/10.1088/2057-1976/aa6db9.
    Full Text Open Access Copy Link to Item
  - Pozzi, Oscar R., and Michael R. Zalutsky. “Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for ²¹¹At labeling at high activities and radiation doses of ²¹¹At α-particles.” Nuclear Medicine and Biology 46 (March 2017): 43–49. https://doi.org/10.1016/j.nucmedbio.2016.11.009.
    Full Text
  - Chin, Bennett B., Darryl McDougald, Douglas H. Weitzel, Thomas Hawk, Robert E. Reiman, Michael R. Zalutsky, and Ganesan Vaidyanathan. “Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine.” Curr Radiopharm 10, no. 1 (2017): 41–50. https://doi.org/10.2174/1874471009666161230114954.
    Full Text Open Access Copy Link to Item
  - Slastnikova, Tatiana A., Andrey A. Rosenkranz, Natalia B. Morozova, Maria S. Vorontsova, Vasiliy M. Petriev, Tatiana N. Lupanova, Alexey V. Ulasov, Michael R. Zalutsky, Raisa I. Yakubovskaya, and Alexander S. Sobolev. “Preparation, cytotoxicity, and in vivo antitumor efficacy of 111In-labeled modular nanotransporters.” Int J Nanomedicine 12 (2017): 395–410. https://doi.org/10.2147/IJN.S125359.
    Full Text Link to Item
  - Kiess, Ana P., Il Minn, Ganesan Vaidyanathan, Robert F. Hobbs, Anders Josefsson, Colette Shen, Mary Brummet, et al. “(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.” J Nucl Med 57, no. 10 (October 2016): 1569–75. https://doi.org/10.2967/jnumed.116.174300.
    Full Text Link to Item
  - Rowe, Steven P., Alexander Drzezga, Bernd Neumaier, Markus Dietlein, Michael A. Gorin, Michael R. Zalutsky, and Martin G. Pomper. “Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.” J Nucl Med 57, no. Suppl 3 (October 2016): 90S-96S. https://doi.org/10.2967/jnumed.115.170175.
    Full Text Link to Item
  - Chitneni, Satish K., Zachary J. Reitman, David M. Gooden, Hai Yan, and Michael R. Zalutsky. “Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.” Eur J Med Chem 119 (August 25, 2016): 218–30. https://doi.org/10.1016/j.ejmech.2016.04.066.
    Full Text Open Access Copy Link to Item
  - Vaidyanathan, Ganesan, Darryl McDougald, Jaeyeon Choi, Eftychia Koumarianou, Douglas Weitzel, Takuya Osada, H Kim Lyerly, and Michael R. Zalutsky. “Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.” J Nucl Med 57, no. 6 (June 2016): 967–73. https://doi.org/10.2967/jnumed.115.171306.
    Full Text Link to Item
  - Schaal, Jeffrey L., Xinghai Li, Eric Mastria, Jayanta Bhattacharyya, Michael R. Zalutsky, Ashutosh Chilkoti, and Wenge Liu. “Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy.” J Control Release 228 (April 28, 2016): 58–66. https://doi.org/10.1016/j.jconrel.2016.02.040.
    Full Text Link to Item
  - Bao, Xuhui, Vidyalakshmi Chandramohan, Randall P. Reynolds, John N. Norton, William C. Wetsel, Ramona M. Rodriguiz, Dipendra K. Aryal, et al. “Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.” Invest New Drugs 34, no. 2 (April 2016): 149–58. https://doi.org/10.1007/s10637-015-0318-3.
    Full Text Link to Item
  - Mukerji, Ratul, Jeffrey Schaal, Xinghai Li, Jayanta Bhattacharyya, Daisuke Asai, Michael R. Zalutsky, Ashutosh Chilkoti, and Wenge Liu. “Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor.” Biomaterials 79 (February 2016): 79–87. https://doi.org/10.1016/j.biomaterials.2015.11.064.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Darryl McDougald, Jaeyeon Choi, Marek Pruszynski, Eftychia Koumarianou, Zhengyuan Zhou, and Michael R. Zalutsky. “N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules.” Org Biomol Chem 14, no. 4 (January 28, 2016): 1261–71. https://doi.org/10.1039/c5ob02258d.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Darryl McDougald, Eftychia Koumarianou, Jaeyeon Choi, Marc Hens, and Michael R. Zalutsky. “Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.” Nuclear Medicine and Biology 42, no. 8 (August 2015): 673–84. https://doi.org/10.1016/j.nucmedbio.2015.04.005.
    Full Text
  - Pruszyński, Marek, Monika Łyczko, Aleksander Bilewicz, and Michael R. Zalutsky. “Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.” Nucl Med Biol 42, no. 5 (May 2015): 439–45. https://doi.org/10.1016/j.nucmedbio.2014.12.011.
    Full Text Link to Item
  - Chitneni, Satish K., Gerald T. Bida, Michael R. Zalutsky, and Mark W. Dewhirst. “Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding.” J Nucl Med 56, no. 4 (April 2015): 653–54. https://doi.org/10.2967/jnumed.115.154054.
    Full Text Link to Item
  - Liu, Yang, Jeffrey R. Ashton, Everett J. Moding, Hsiangkuo Yuan, Janna K. Register, Andrew M. Fales, Jaeyeon Choi, et al. “A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy.” Theranostics 5, no. 9 (2015): 946–60. https://doi.org/10.7150/thno.11974.
    Full Text Open Access Copy Link to Item
  - Pruszynski, Marek, Eftychia Koumarianou, Ganesan Vaidyanathan, Satish Chitneni, and Michael R. Zalutsky. “D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.” Nucl Med Biol 42, no. 1 (January 2015): 19–27. https://doi.org/10.1016/j.nucmedbio.2014.08.007.
    Full Text Open Access Copy Link to Item
  - Slastnikova, T. A., A. A. Rosenkranz, M. R. Zalutsky, and A. S. Sobolev. “Modular nanotransporters for targeted intracellular delivery of drugs: Folate receptors as potential targets.” Current Pharmaceutical Design 21, no. 9 (2015): 1227–38.
  - Slastnikova, Tatiana A., Andrey A. Rosenkranz, Michael R. Zalutsky, and Alexander S. Sobolev. “Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.” Curr Pharm Des 21, no. 9 (2015): 1227–38. https://doi.org/10.2174/1381612820666141013121032.
    Full Text Link to Item
  - Choi, Jaeyeon, Ganesan Vaidyanathan, Eftychia Koumarianou, Darryl McDougald, Marek Pruszynski, Takuya Osada, Tony Lahoutte, H Kim Lyerly, and Michael R. Zalutsky. “N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.” Nuclear Medicine and Biology 41, no. 10 (November 2014): 802–12. https://doi.org/10.1016/j.nucmedbio.2014.07.005.
    Full Text
  - Safi, Rachid, Erik R. Nelson, Satish K. Chitneni, Katherine J. Franz, Daniel J. George, Michael R. Zalutsky, and Donald P. McDonnell. “Copper signaling axis as a target for prostate cancer therapeutics.” Cancer Res 74, no. 20 (October 15, 2014): 5819–31. https://doi.org/10.1158/0008-5472.CAN-13-3527.
    Full Text Open Access Copy Link to Item
  - Chitneni, Satish K., Gerald T. Bida, Michael R. Zalutsky, and Mark W. Dewhirst. “Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 55, no. 7 (July 2014): 1192–97. https://doi.org/10.2967/jnumed.114.137448.
    Full Text
  - Koumarianou, Eftychia, Tatiana A. Slastnikova, Marek Pruszynski, Andrey A. Rosenkranz, Ganesan Vaidyanathan, Alexander S. Sobolev, and Michael R. Zalutsky. “Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic.” Nuclear Medicine and Biology 41, no. 6 (July 2014): 441–49. https://doi.org/10.1016/j.nucmedbio.2014.03.026.
    Full Text
  - Pruszynski, Marek, Eftychia Koumarianou, Ganesan Vaidyanathan, Hilde Revets, Nick Devoogdt, Tony Lahoutte, H Kim Lyerly, and Michael R. Zalutsky. “Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.” J Nucl Med 55, no. 4 (April 2014): 650–56. https://doi.org/10.2967/jnumed.113.127100.
    Full Text Link to Item
  - Barrott, Jared J., Philip F. Hughes, Takuya Osada, Xiao-Yi Yang, Zachary C. Hartman, David R. Loiselle, Neil L. Spector, et al. “Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.” Chem Biol 20, no. 9 (September 19, 2013): 1187–97. https://doi.org/10.1016/j.chembiol.2013.08.004.
    Full Text Link to Item
  - Chitneni, Satish K., Gerald T. Bida, Hong Yuan, Gregory M. Palmer, Michael P. Hay, Thorsten Melcher, William R. Wilson, Michael R. Zalutsky, and Mark W. Dewhirst. “18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.” J Nucl Med 54, no. 8 (August 2013): 1339–46. https://doi.org/10.2967/jnumed.112.116293.
    Full Text Link to Item
  - Choi, Jaeyeon, Ganesan Vaidyanathan, Eftychia Koumarianou, Marek Pruszynski, Tony Lahoutte, and Michael Rod Zalutsky. “Isomeric N-succinimidyl 3-guanidinomethyl-5-[I-131]iodobenzoate (iso-[I-131]SGMIB): A guanidine-containing residualizing agent for radiohalogenation of internalizing biomolecules.” Journal of Labelled Compounds & Radiopharmaceuticals 56 (May 1, 2013): S39–S39.
    Link to Item
  - Vaidyanathan, Ganesan, Darryl McDougald, Marek Pruszynski, Eftychia Koumarianou, Marc Anton Hens, Tony Lahoutte, and Michael Rod Zalutsky. “SFBTMGMB (N-succinimidyl 3-((4-(4-fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate): An SGMIB analogue for labeling internalizing biomolecules with F-18.” Journal of Labelled Compounds & Radiopharmaceuticals 56 (May 1, 2013): S127–S127.
    Link to Item
  - Pruszynski, Marek, Eftychia Koumarianou, Ganesan Vaidyanathan, Hilde Revets, Nick Devoogdt, Tony Lahoutte, and Michael R. Zalutsky. “Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.” Nucl Med Biol 40, no. 1 (January 2013): 52–59. https://doi.org/10.1016/j.nucmedbio.2012.08.008.
    Full Text Link to Item
  - Vaidyanathan, G., B. J. White, D. J. Affleck, X. G. Zhao, P. C. Welsh, D. McDougald, J. Choi, and M. R. Zalutsky. “SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.” Bioorg Med Chem 20, no. 24 (December 15, 2012): 6929–39. https://doi.org/10.1016/j.bmc.2012.10.025.
    Full Text Link to Item
  - Liu, Wenge, Jonathan McDaniel, Xinghai Li, Daisuke Asai, Felipe Garcia Quiroz, Jeffery Schaal, Ji Sun Park, Michael Zalutsky, and Ashutosh Chilkoti. “Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ.” Cancer Res 72, no. 22 (November 15, 2012): 5956–65. https://doi.org/10.1158/0008-5472.CAN-12-2127.
    Full Text Link to Item
  - Slastnikova, Tatiana A., Eftychia Koumarianou, Andrey A. Rosenkranz, Ganesan Vaidyanathan, Tatiana N. Lupanova, Alexander S. Sobolev, and Michael R. Zalutsky. “Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I.” Ejnmmi Res 2, no. 1 (October 29, 2012): 59. https://doi.org/10.1186/2191-219X-2-59.
    Full Text Open Access Copy Link to Item
  - Chitneni, Satish K., Gerald T. Bida, Mark W. Dewhirst, and Michael R. Zalutsky. “A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).” Nucl Med Biol 39, no. 7 (October 2012): 1012–18. https://doi.org/10.1016/j.nucmedbio.2012.05.006.
    Full Text Link to Item
  - Asai, Daisuke, Donghua Xu, Wenge Liu, Felipe Garcia Quiroz, Daniel J. Callahan, Michael R. Zalutsky, Stephen L. Craig, and Ashutosh Chilkoti. “Protein polymer hydrogels by in situ, rapid and reversible self-gelation.” Biomaterials 33, no. 21 (July 2012): 5451–58. https://doi.org/10.1016/j.biomaterials.2012.03.083.
    Full Text Link to Item
  - Liu, Wenge, Jonathan R. McDaniel, Xinghai Li, Daisuke Asai, Michael R. Zalutsky, and Ashutosh Chilkoti. “Abstract 2884: Preclinical studies on tumor retention, antitumor efficacy and toxicity of thermally responsive polypeptide-based radionuclide intratumoral depot in nude mice.” Cancer Chemistry, April 15, 2012. https://doi.org/10.1158/1538-7445.am2012-2884.
    Full Text
  - Slastnikova, Tatiana A., Andrey A. Rosenkranz, Pavel V. Gulak, Raymond M. Schiffelers, Tatiana N. Lupanova, Yuri V. Khramtsov, Michael R. Zalutsky, and Alexander S. Sobolev. “Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery.” Int J Nanomedicine 7 (2012): 467–82. https://doi.org/10.2147/IJN.S28249.
    Full Text Open Access Copy Link to Item
  - Zalutsky, Michael R., Abraham Boskovitz, Chien-Tsun Kuan, Charles N. Pegram, Joanne Ayriss, Carol J. Wikstrand, Anne F. Buckley, et al. “Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.” Nucl Med Biol 39, no. 1 (January 2012): 23–34. https://doi.org/10.1016/j.nucmedbio.2011.06.005.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Darryl McDougald, Linda Grasfeder, Michael R. Zalutsky, and Bennett Chin. “An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine.” Appl Radiat Isot 69, no. 10 (October 2011): 1401–6. https://doi.org/10.1016/j.apradiso.2011.05.004.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, and Michael R. Zalutsky. “Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.” Curr Radiopharm 4, no. 4 (October 2011): 283–94. https://doi.org/10.2174/1874471011104040283.
    Full Text Link to Item
  - Sampson, John H., Martin Brady, Raghu Raghavan, Ankit I. Mehta, Allan H. Friedman, David A. Reardon, Neil A. Petry, et al. “Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.” Neurosurgery 69, no. 3 (September 2011): 668–76. https://doi.org/10.1227/NEU.0b013e3182181ba8.
    Full Text Link to Item
  - Zalutsky, Michael R., and Marek Pruszynski. “Astatine-211: production and availability.” Curr Radiopharm 4, no. 3 (July 2011): 177–85. https://doi.org/10.2174/1874471011104030177.
    Full Text Link to Item
  - Chitneni, Satish K., Gerald T. Bida, Michael P. Hay, Michael R. Zalutsky, Thorsten Melcher, William R. Wilson, and Mark W. Dewhirst. “Abstract 5306:18F-EF5 microPET imaging of treatment response from a novel, hypoxia-selective cytotoxin SN30000 in a human lung cancer xenograft model.” Tumor Biology, April 15, 2011. https://doi.org/10.1158/1538-7445.am2011-5306.
    Full Text
  - Chitneni, Satish K., Gregory M. Palmer, Michael R. Zalutsky, and Mark W. Dewhirst. “Molecular imaging of hypoxia.” J Nucl Med 52, no. 2 (February 2011): 165–68. https://doi.org/10.2967/jnumed.110.075663.
    Full Text Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Applications of ²¹¹AT and ²²³RA in targeted alpha-particle radiotherapy.” Current Radiopharmaceuticals 4, no. 4 (2011): 283–94.
  - Vaidyanathan, Ganesan, Benjamin White, Donna J. Affleck, Darryl McDougald, and Michael R. Zalutsky. “Radioiodinated O(6)-Benzylguanine derivatives containing an azido function.” Nucl Med Biol 38, no. 1 (January 2011): 77–92. https://doi.org/10.1016/j.nucmedbio.2010.07.006.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Darryl McDougald, Donna J. Affleck, and Michael R. Zalutsky. “A tin precursor of SGMIB potentially useful in the direct modification of peptides and proteins before radiohalogenation.” Journal of Labelled Compounds & Radiopharmaceuticals 54 (January 1, 2011): S64–S64.
    Link to Item
  - Hens, Marc, Ganesan Vaidyanathan, Xiao-Guang Zhao, Darell D. Bigner, and Michael R. Zalutsky. “Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.” Nucl Med Biol 37, no. 7 (October 2010): 741–50. https://doi.org/10.1016/j.nucmedbio.2010.04.020.
    Full Text Link to Item
  - Kato, Yukinari, Ganesan Vaidyanathan, Mika Kato Kaneko, Kazuhiko Mishima, Nidhi Srivastava, Vidyalakshmi Chandramohan, Charles Pegram, et al. “Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.” Nucl Med Biol 37, no. 7 (October 2010): 785–94. https://doi.org/10.1016/j.nucmedbio.2010.03.010.
    Full Text Link to Item
  - Gao, Weiping, Wenge Liu, Trine Christensen, Michael R. Zalutsky, and Ashutosh Chilkoti. “In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation.” Proc Natl Acad Sci U S A 107, no. 38 (September 21, 2010): 16432–37. https://doi.org/10.1073/pnas.1006044107.
    Full Text Link to Item
  - Kuan, Chien-Tsun, Nidhi Srivastava, Roger E. McLendon, Wayne A. Marasco, Michael R. Zalutsky, and Darell D. Bigner. “Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.” Int J Cancer 127, no. 3 (August 1, 2010): 598–611. https://doi.org/10.1002/ijc.25062.
    Full Text Link to Item
  - Zalutsky, M. R., D. A. Reardon, and D. D. Bigner. “Targeted Radiotherapy of Central Nervous System Malignancies,” July 15, 2010, 139–67. https://doi.org/10.1002/9780470613214.ch5.
    Full Text
  - Liu, Wenge, J Andrew MacKay, Matthew R. Dreher, Mingnan Chen, Jonathan R. McDaniel, Andrew J. Simnick, Daniel J. Callahan, Michael R. Zalutsky, and Ashutosh Chilkoti. “Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model.” J Control Release 144, no. 1 (May 21, 2010): 2–9. https://doi.org/10.1016/j.jconrel.2010.01.032.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Donna J. Affleck, Xiao-Guang Zhao, Stephen T. Keir, and Michael R. Zalutsky. “[Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.” Curr Radiopharm 3, no. 1 (2010): 29–36. https://doi.org/10.2174/1874471011003010029.
    Full Text Link to Item
  - Kuan, Chien-Tsun, Carol J. Wikstrand, Roger E. McLendon, Michael R. Zalutsky, Ujendra Kumar, and Darell D. Bigner. “Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.” Hybridoma (Larchmt) 28, no. 6 (December 2009): 389–403. https://doi.org/10.1089/hyb.2009.0049.
    Full Text Open Access Copy Link to Item
  - Vaidyanathan, Ganesan, Haijing Song, Donna Affleck, Darryl L. McDougald, Robert W. Storms, Michael R. Zalutsky, and Bennett B. Chin. “Targeting aldehyde dehydrogenase: a potential approach for cell labeling.” Nucl Med Biol 36, no. 8 (November 2009): 919–29. https://doi.org/10.1016/j.nucmedbio.2009.08.001.
    Full Text Link to Item
  - Gao, Weiping, Wenge Liu, J Andrew Mackay, Michael R. Zalutsky, Eric J. Toone, and Ashutosh Chilkoti. “In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics.” Proc Natl Acad Sci U S A 106, no. 36 (September 8, 2009): 15231–36. https://doi.org/10.1073/pnas.0904378106.
    Full Text Link to Item
  - Boskovitz, Abraham, Roger E. McLendon, Tatsunori Okamura, John H. Sampson, Darell D. Bigner, and Michael R. Zalutsky. “Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.” Nucl Med Biol 36, no. 6 (August 2009): 659–69. https://doi.org/10.1016/j.nucmedbio.2009.04.003.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Emmanuelle Jestin, Tove Olafsen, Anna M. Wu, and Michael R. Zalutsky. “Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.” Nucl Med Biol 36, no. 6 (August 2009): 671–80. https://doi.org/10.1016/j.nucmedbio.2009.04.002.
    Full Text Link to Item
  - Kuan, Chien-Tsun, Kenji Wakiya, James E. Herndon, Carol J. Wikstrand, Roger E. McLendon, Michael R. Zalutsky, Ira H. Pastan, and Darell D. Bigner. “RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY.” Neuro Oncology 11, no. 2 (April 1, 2009): 224–224.
    Link to Item
  - Hens, Marc, Ganesan Vaidyanathan, Phil Welsh, and Michael R. Zalutsky. “Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.” Nucl Med Biol 36, no. 2 (February 2009): 117–28. https://doi.org/10.1016/j.nucmedbio.2008.11.001.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Benjamin J. White, and Michael R. Zalutsky. “Propargyl 4-[F]fluorobenzoate: A Putatively More Stable Prosthetic group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry.” Curr Radiopharm 2, no. 1 (January 1, 2009): 63–74. https://doi.org/10.2174/1874471010902010063.
    Full Text Link to Item
  - Rosenkranz, Andrey A., Ganesan Vaidyanathan, Oscar R. Pozzi, Vladimir G. Lunin, Michael R. Zalutsky, and Alexander S. Sobolev. “Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.” Int J Radiat Oncol Biol Phys 72, no. 1 (September 1, 2008): 193–200. https://doi.org/10.1016/j.ijrobp.2008.05.055.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, and Michael R. Zalutsky. “Astatine Radiopharmaceuticals: Prospects and Problems.” Curr Radiopharm 1, no. 3 (September 1, 2008): 177. https://doi.org/10.2174/1874471010801030177.
    Full Text Link to Item
  - Sampson, John H., Gamal Akabani, Gerald E. Archer, Mitchel S. Berger, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, et al. “Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.” Neuro Oncol 10, no. 3 (June 2008): 320–29. https://doi.org/10.1215/15228517-2008-012.
    Full Text Link to Item
  - Pruszyński, Marek, Aleksander Bilewicz, and Michael R. Zalutsky. “Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.” Bioconjug Chem 19, no. 4 (April 2008): 958–65. https://doi.org/10.1021/bc700413r.
    Full Text Link to Item
  - Reardon, David A., Michael R. Zalutsky, Gamal Akabani, R Edward Coleman, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.” Neuro Oncol 10, no. 2 (April 2008): 182–89. https://doi.org/10.1215/15228517-2007-053.
    Full Text Link to Item
  - Zalutsky, Michael R., David A. Reardon, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, Roger E. McLendon, Terence Z. Wong, and Darell D. Bigner. “Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.” J Nucl Med 49, no. 1 (January 2008): 30–38. https://doi.org/10.2967/jnumed.107.046938.
    Full Text Link to Item
  - Petrik, M., A. Laznickova, M. Laznicek, and M. R. Zalutsky. “Radiolabelling of glucose-Tyr³-octreotate with ¹²⁵I and analysis of its metabolism in rats: Comparison with radiolabelled DOTA-Tyr³-octreotate.” Anticancer Research 27, no. 6 B (November 1, 2007): 3941–46.
  - Petrik, Milos, Alice Laznickova, Milan Laznicek, and Michael R. Zalutsky. “Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.” Anticancer Res 27, no. 6B (November 2007): 3941–46.
    Link to Item
  - Vaidyanathan, Ganesan, Donna J. Affleck, Joseph Norman, Susan O’Dorisio, and Michael R. Zalutsky. “A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.” Bioconjug Chem 18, no. 6 (November 2007): 2122–30. https://doi.org/10.1021/bc700240r.
    Full Text Link to Item
  - Zalutsky, Michael R., David A. Reardon, Oscar R. Pozzi, Ganesan Vaidyanathan, and Darell D. Bigner. “Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.” Nucl Med Biol 34, no. 7 (October 2007): 779–85. https://doi.org/10.1016/j.nucmedbio.2007.03.007.
    Full Text Link to Item
  - Pozzi, Oscar R., and Michael R. Zalutsky. “Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.” J Nucl Med 48, no. 7 (July 2007): 1190–96. https://doi.org/10.2967/jnumed.106.038505.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Donna J. Affleck, Kevin L. Alston, Xiao-Guang Zhao, Marc Hens, Duncan H. Hunter, John Babich, and Michael R. Zalutsky. “A kit method for the high level synthesis of [211At]MABG.” Bioorg Med Chem 15, no. 10 (May 15, 2007): 3430–36. https://doi.org/10.1016/j.bmc.2007.03.016.
    Full Text Link to Item
  - McLendon, Roger E., Gamal Akabani, Henry S. Friedman, David A. Reardon, Linda Cleveland, Ilkcan Cokgor, James E. Herndon, et al. “Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.” Nucl Med Biol 34, no. 4 (May 2007): 405–13. https://doi.org/10.1016/j.nucmedbio.2007.01.009.
    Full Text Link to Item
  - Reardon, David A., Michael R. Zalutsky, and Darell D. Bigner. “Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.” Expert Rev Anticancer Ther 7, no. 5 (May 2007): 675–87. https://doi.org/10.1586/14737140.7.5.675.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, K. L. Alston, and M. R. Zalutsky. “A tin precursor for the synthesis of no-carrier-added [*I]MIBG and [²¹¹At]MABG.” Journal of Labelled Compounds and Radiopharmaceuticals 50, no. 3 (March 1, 2007): 177–82. https://doi.org/10.1002/jlcr.1243.
    Full Text
  - Yordanov, Alexander T., Marc Hens, Charles Pegram, Darell D. Bigner, and Michael R. Zalutsky. “Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.” Nucl Med Biol 34, no. 2 (February 2007): 173–83. https://doi.org/10.1016/j.nucmedbio.2006.11.003.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, and Michael R. Zalutsky. “Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides.” Nat Protoc 2, no. 2 (2007): 282–86. https://doi.org/10.1038/nprot.2007.20.
    Full Text Link to Item
  - Liu, Wenge, Matthew R. Dreher, Darin Y. Furgeson, Katia V. Peixoto, Hong Yuan, Michael R. Zalutsky, and Ashutosh Chilkoti. “Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice.” J Control Release 116, no. 2 (November 28, 2006): 170–78. https://doi.org/10.1016/j.jconrel.2006.06.026.
    Full Text Link to Item
  - Betre, Helawe, Wenge Liu, Michael R. Zalutsky, Ashutosh Chilkoti, Virginia B. Kraus, and Lori A. Setton. “A thermally responsive biopolymer for intra-articular drug delivery.” J Control Release 115, no. 2 (October 10, 2006): 175–82. https://doi.org/10.1016/j.jconrel.2006.07.022.
    Full Text Link to Item
  - Boskovitz, A., H. Ochiai, T. Okamura, G. Akabani, S. Carlin, D. D. Bigner, and M. R. Zalutsky. “At-211-labeled trastuzumab: Evaluation of an alpha-particle emitting targeted radiotherapeutic for the treatment of breast carcinoma carcinomatous meningitis.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S184–S184.
    Link to Item
  - Boskovitz, A., H. Ochiai, T. Okamura, G. Akabani, S. Carlin, D. D. Bigner, and M. R. Zalutsky. “At-211-labeled trastuzumab: Evaluation of an alpha-particle emitting targeted radiotherapeutic for the treatment of breast carcinoma carcinomatous meningitis.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S378–S378.
    Link to Item
  - Laznickova, A., M. Petrik, L. Melicharova, M. Laznicek, and M. R. Zalutsky. “Preclinical pharmacokinetic comparison of glucose-125I-Tyr3-octreotate with DOTA-125I-Tyr3-octreotate.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S307–8.
    Link to Item
  - Reardon, D. A., M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, R. E. McLendon, H. S. Friedman, J. E. Herndon, J. Kirkpatrick, and D. D. Bigner. “Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S194–S194.
    Link to Item
  - Zalutsky, M. R., D. A. Reardon, J. A. Quinn, R. E. Coleman, G. Akabani, A. H. Friedman, H. S. Friedman, et al. “Chimeric murine/human IgG(2) anti-tenascin 81C6 monoclonal antibody: phase I trial in patients with malignant glioma of a construct with improved stability.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S194–S194.
    Link to Item
  - Liu, Wenge, Matthew R. Dreher, Dominic C. Chow, Michael R. Zalutsky, and Ashutosh Chilkoti. “Tracking the in vivo fate of recombinant polypeptides by isotopic labeling.” J Control Release 114, no. 2 (August 28, 2006): 184–92. https://doi.org/10.1016/j.jconrel.2006.06.001.
    Full Text Link to Item
  - Zalutsky, Michael R. “Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.” J Nucl Med 47, no. 8 (August 2006): 1238–40.
    Link to Item
  - Vaidyanathan, Ganesan, Kevin L. Alston, Darrel D. Bigner, and Michael R. Zalutsky. “Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.” Bioconjug Chem 17, no. 4 (July 2006): 1085–92. https://doi.org/10.1021/bc0600766.
    Full Text Link to Item
  - Boyd, Marie, Susan C. Ross, Jennifer Dorrens, Natasha E. Fullerton, Ker Wei Tan, Michael R. Zalutsky, and Robert J. Mairs. “Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.” J Nucl Med 47, no. 6 (June 2006): 1007–15.
    Link to Item
  - Reardon, David A., Jennifer A. Quinn, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, et al. “Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.” J Nucl Med 47, no. 6 (June 2006): 912–18.
    Link to Item
  - Akabani, Gamal, Sean Carlin, Phil Welsh, and Michael R. Zalutsky. “In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.” Nucl Med Biol 33, no. 3 (April 2006): 333–47. https://doi.org/10.1016/j.nucmedbio.2005.12.006.
    Full Text Link to Item
  - Shankar, Sriram, Michael R. Zalutsky, Henry Friedman, and Ganesan Vaidyanathan. “Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine.” Nucl Med Biol 33, no. 3 (April 2006): 399–407. https://doi.org/10.1016/j.nucmedbio.2005.12.015.
    Full Text Link to Item
  - Zalutsky, Michael R. “Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning.” Clin Cancer Res 12, no. 7 Pt 1 (April 1, 2006): 1958–60. https://doi.org/10.1158/1078-0432.CCR-06-0405.
    Full Text Link to Item
  - Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, et al. “Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.” J Clin Oncol 24, no. 1 (January 1, 2006): 115–22. https://doi.org/10.1200/JCO.2005.03.4082.
    Full Text Link to Item
  - Shankar, Sriram, Ganesan Vaidyanathan, Chien-Tsun Kuan, Darell D. Bigner, and Michael R. Zalutsky. “Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.” Nucl Med Biol 33, no. 1 (January 2006): 101–10. https://doi.org/10.1016/j.nucmedbio.2005.08.004.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, M. Schottelius, H. Wester, H. S. Friedman, and M. R. Zalutsky. “Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor.” Bioconjug Chem 17, no. 1 (January 2006): 195–203. https://doi.org/10.1021/bc0502560.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, and Michael R. Zalutsky. “Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins.” Nat Protoc 1, no. 2 (2006): 707–13. https://doi.org/10.1038/nprot.2006.99.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, and Michael R. Zalutsky. “Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F.” Nat Protoc 1, no. 4 (2006): 1655–61. https://doi.org/10.1038/nprot.2006.264.
    Full Text Link to Item
  - Fullerton, Natasha E., Marie Boyd, Susan C. Ross, Sally L. Pimlott, John Babich, David Kirk, Michael R. Zalutsky, and Robert J. Mairs. “Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.” Med Chem 1, no. 6 (November 2005): 611–18. https://doi.org/10.2174/157340605774598090.
    Full Text Link to Item
  - Pozzi, Oscar R., and Michael R. Zalutsky. “Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.” J Nucl Med 46, no. 8 (August 2005): 1393–1400.
    Link to Item
  - Shankar, Sriram, Michael R. Zalutsky, and Ganesan Vaidyanathan. “O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT).” Bioorg Med Chem 13, no. 12 (June 2, 2005): 3889–98. https://doi.org/10.1016/j.bmc.2005.04.014.
    Full Text Link to Item
  - Akabani, Gamal, David A. Reardon, R Edward Coleman, Terence Z. Wong, Scott D. Metzler, James E. Bowsher, Daniel P. Barboriak, et al. “Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.” J Nucl Med 46, no. 6 (June 2005): 1042–51.
    Link to Item
  - Pozzi, Oscar R., and Michael R. Zalutsky. “Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.” J Nucl Med 46, no. 4 (April 2005): 700–706.
    Link to Item
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.” Appl Radiat Isot 62, no. 3 (March 2005): 435–40. https://doi.org/10.1016/j.apradiso.2004.07.001.
    Full Text Link to Item
  - Hauck, M. L., and M. R. Zalutsky. “Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation.” Int J Hyperthermia 21, no. 1 (February 2005): 13–27. https://doi.org/10.1080/02656730400011032.
    Full Text Link to Item
  - Hauck, M. L., and M. R. Zalutsky. “Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.” Int J Hyperthermia 21, no. 1 (February 2005): 1–11. https://doi.org/10.1080/02656730410001695906.
    Full Text Link to Item
  - Zalutsky, Michael R. “Current status of therapy of solid tumors: brain tumor therapy.” J Nucl Med 46 Suppl 1 (January 2005): 151S-156S.
    Link to Item
  - Vaidyanathan, Ganesan, Abraham Boskovitz, Sriram Shankar, and Michael R. Zalutsky. “Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers.” Peptides 25, no. 12 (December 2004): 2087–97. https://doi.org/10.1016/j.peptides.2004.08.018.
    Full Text Link to Item
  - Yordanov, A. T., O. Pozzi, S. Carlin, G. Akabani, B. Wieland, and M. R. Zalutsky. “Wet harvesting of no-carrier-added ²¹¹At from an irradiated ²⁰⁹Bi target for radiopharmaceutical applications.” Journal of Radioanalytical and Nuclear Chemistry 262, no. 3 (December 1, 2004): 593–99. https://doi.org/10.1007/s10967-004-0481-z.
    Full Text
  - Zalutsky, M. R., and O. R. Pozzi. “Radioimmunotherapy with alpha-particle emitting radionuclides.” Q J Nucl Med Mol Imaging 48, no. 4 (December 2004): 289–96.
    Link to Item
  - Shankar, Sriram, Ganesan Vaidyanathan, Donna J. Affleck, Katia Peixoto, Darell D. Bigner, and Michael R. Zalutsky. “Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.” Nucl Med Biol 31, no. 7 (October 2004): 909–19. https://doi.org/10.1016/j.nucmedbio.2004.04.007.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Philip C. Welsh, Katia C. Vitorello, Stacey Snyder, Henry S. Friedman, and Michael R. Zalutsky. “A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.” Eur J Nucl Med Mol Imaging 31, no. 10 (October 2004): 1362–70. https://doi.org/10.1007/s00259-004-1596-8.
    Full Text Link to Item
  - Boskovitz, Abraham, Carol J. Wikstrand, Chien-Tsun Kuan, Michael R. Zalutsky, David A. Reardon, and Darell D. Bigner. “Monoclonal antibodies for brain tumour treatment.” Expert Opin Biol Ther 4, no. 9 (September 2004): 1453–71. https://doi.org/10.1517/14712598.4.9.1453.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Donna J. Affleck, Kevin L. Alston, Philip Welsh, and Michael R. Zalutsky. “Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.” Nucl Med Commun 25, no. 9 (September 2004): 947–55. https://doi.org/10.1097/00006231-200409000-00013.
    Full Text Link to Item
  - Boyd, Marie, Robert J. Mairs, W Nicol Keith, Susan C. Ross, Philip Welsh, Gamal Akabani, Jonathan Owens, et al. “An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.” J Gene Med 6, no. 8 (August 2004): 937–47. https://doi.org/10.1002/jgm.578.
    Full Text Link to Item
  - Rizzieri, David A., Gamal Akabani, Michael R. Zalutsky, R Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, et al. “Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.” Blood 104, no. 3 (August 1, 2004): 642–48. https://doi.org/10.1182/blood-2003-12-4264.
    Full Text Link to Item
  - Zalutsky, M. R. “Targeted radiotherapy of brain tumours.” Br J Cancer 90, no. 8 (April 19, 2004): 1469–73. https://doi.org/10.1038/sj.bjc.6601771.
    Full Text Open Access Copy Link to Item
  - Boskovitz, Abraham, Gamal H. Akabani, Charles N. Pegram, Darrell D. Bigner, and Michael R. Zalutsky. “Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.” Nucl Med Biol 31, no. 3 (April 2004): 345–55. https://doi.org/10.1016/j.nucmedbio.2003.10.008.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Sriram Shankar, Donna J. Affleck, Kevin Alston, Joseph Norman, Philip Welsh, Holly LeGrand, and Michael R. Zalutsky. “Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.” Bioorg Med Chem 12, no. 7 (April 1, 2004): 1649–56. https://doi.org/10.1016/j.bmc.2004.01.026.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Donna J. Affleck, Joseph Norman, Phil Welsh, Wenge Liu, Stewart P. Johnson, Henry S. Friedman, and Michael R. Zalutsky. “O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase.” Bioconjug Chem 15, no. 2 (March 2004): 402–8. https://doi.org/10.1021/bc0341977.
    Full Text Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Imaging drug resistance with radiolabeled molecules.” Curr Pharm Des 10, no. 24 (2004): 2965–79. https://doi.org/10.2174/1381612043383449.
    Full Text Link to Item
  - Zalutsky, Michael R., and Barbara Petelenz. “Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland.” Nucl Med Rev Cent East Eur 7, no. 2 (2004): 195.
    Link to Item
  - Wilbur, D Scott, Ming-Kuan Chyan, Donald K. Hamlin, Brian B. Kegley, Reudi Risler, Pradip M. Pathare, Janna Quinn, et al. “Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.” Bioconjug Chem 15, no. 1 (January 2004): 203–23. https://doi.org/10.1021/bc034175k.
    Full Text Link to Item
  - Grossi, Peter M., Hidenobu Ochiai, Gary E. Archer, Roger E. McLendon, Michael R. Zalutsky, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.” Clin Cancer Res 9, no. 15 (November 15, 2003): 5514–20.
    Link to Item
  - Carlin, Sean, Gamal Akabani, and Michael R. Zalutsky. “In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.” J Nucl Med 44, no. 11 (November 2003): 1827–38.
    Link to Item
  - Sampson, John H., Gamal Akabani, Gary E. Archer, Darell D. Bigner, Mitchel S. Berger, Allan H. Friedman, Henry S. Friedman, et al. “Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.” J Neurooncol 65, no. 1 (October 2003): 27–35. https://doi.org/10.1023/a:1026290315809.
    Full Text Link to Item
  - Akabani, Gamal, Stephen J. Kennel, and Michael R. Zalutsky. “Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.” J Nucl Med 44, no. 5 (May 2003): 792–805.
    Link to Item
  - Vaidyanathan, Ganesan, Donna J. Affleck, Darell D. Bigner, and Michael R. Zalutsky. “N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.” Nucl Med Biol 30, no. 4 (May 2003): 351–59. https://doi.org/10.1016/s0969-8051(03)00005-2.
    Full Text Link to Item
  - Vaidyanathan, Ganesan, Henry S. Friedman, Donna J. Affleck, Margaret Schottelius, Hans-Jürgen Wester, and Michael R. Zalutsky. “Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.” Clin Cancer Res 9, no. 5 (May 2003): 1868–76.
    Link to Item
  - Shankar, Sriram, Ganesan Vaidyanathan, Donna Affleck, Phillip C. Welsh, and Michael R. Zalutsky. “N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs.” Bioconjug Chem 14, no. 2 (March 2003): 331–41. https://doi.org/10.1021/bc025636p.
    Full Text Link to Item
  - Akabani, Gamal, Roger E. McLendon, Darrell D. Bigner, and Michael R. Zalutsky. “Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.” Int J Radiat Oncol Biol Phys 54, no. 4 (November 15, 2002): 1259–75. https://doi.org/10.1016/s0360-3016(02)03794-x.
    Full Text Link to Item
  - Carlin, Sean, Robert J. Mairs, Phil Welsh, and Michael R. Zalutsky. “Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.” Nucl Med Biol 29, no. 7 (October 2002): 729–39. https://doi.org/10.1016/s0969-8051(02)00332-3.
    Full Text Link to Item
  - Akabani, G., D. Rizzieri, R. E. Coleman, S. D. Metzler, M. R. Zalutsky, and D. D. Bigner. “Radioimmunotherapy of refractory non-Hodgkin's lymphoma with I-131-labeled chimeric 81C6 anti-tenascin monoclonal antibody: Dosimetry study.” Journal of Nuclear Medicine 43, no. 5 (May 1, 2002): 313P-313P.
    Link to Item
  - Shankar, S., G. Vaidyanathan, D. J. Affleck, P. Welsh, H. LeGrand, and M. R. Zalutsky. “Negatively charged substituent-bearing acylation agent for the radiohalogenation of mAbs.” Journal of Nuclear Medicine 43, no. 5 (May 1, 2002): 366P-366P.
    Link to Item
  - Vaidyanathan, G., D. J. Affleck, P. Welsh, M. Schottelius, H. Wester, J. A. Norman, K. L. Alston, and M. R. Zalutsky. “Synthesis and in vitro evaluation of glycated octreotate conjugates labeled with radioiodine and At-211 via a tin precursor.” Journal of Nuclear Medicine 43, no. 5 (May 1, 2002): 92P-92P.
    Link to Item
  - Berry, Clifford R., Timothy R. DeGrado, Felicia Nutter, Pradeep K. Garg, Edward B. Breitschwerdt, Kathy Spaulding, Kevin D. Concannon, Michael R. Zalutsky, and R Edward Coleman. “Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine.” Vet Radiol Ultrasound 43, no. 2 (March 2002): 183–86. https://doi.org/10.1111/j.1740-8261.2002.tb01667.x.
    Full Text Link to Item
  - Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, et al. “Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.” J Clin Oncol 20, no. 5 (March 1, 2002): 1389–97. https://doi.org/10.1200/JCO.2002.20.5.1389.
    Full Text Link to Item
  - Reardon, David A., Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, et al. “Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas.” Journal of Clinical Oncology 20, no. 5 (March 1, 2002): 1389–97. https://doi.org/10.1200/jco.2002.20.5.1389.
    Full Text
  - Vaidyanathan, Ganesan, Donna J. Affleck, Darell D. Bigner, and Michael R. Zalutsky. “Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.” Nucl Med Biol 29, no. 1 (January 2002): 1–11. https://doi.org/10.1016/s0969-8051(01)00277-3.
    Full Text Link to Item
  - Rizzieri, D. A., G. Akabani, R. E. Coleman, M. R. Zalutsky, D. Niedzwiecki, N. Payne, C. Wikstrand, and D. D. Bigner. “Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL).” Blood 98, no. 11 (November 16, 2001): 247B-247B.
    Link to Item
  - Foulon, C. F., P. C. Welsh, D. D. Bigner, and M. R. Zalutsky. “Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.” Nucl Med Biol 28, no. 7 (October 2001): 769–77. https://doi.org/10.1016/s0969-8051(01)00239-6.
    Full Text Link to Item
  - Zalutsky, M. R., X. G. Zhao, K. L. Alston, and D. Bigner. “High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.” J Nucl Med 42, no. 10 (October 2001): 1508–15.
    Link to Item
  - Vaidyanathan, G., S. Shankar, D. J. Affleck, P. C. Welsh, S. K. Slade, and M. R. Zalutsky. “Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues.” Bioconjug Chem 12, no. 5 (September 2001): 798–806. https://doi.org/10.1021/bc010032r.
    Full Text Link to Item
  - Vaidyanathan, G., S. Shankar, and M. R. Zalutsky. “Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues.” Bioconjug Chem 12, no. 5 (September 2001): 786–97. https://doi.org/10.1021/bc010031z.
    Full Text Link to Item
  - Mairs, R. J., S. Carlin, M. Boyd, S. H. Cunningham, P. Welsh, and M. R. Zalutsky. “Transfection of the sodium iodide symporter gene for tumour targeting with radioiodine and [At-211]radioastatine.” British Journal of Cancer 85 (July 1, 2001): 24–24.
    Link to Item
  - Cokgor, I., G. Akabani, H. S. Friedman, A. H. Friedman, M. R. Zalutsky, L. M. Zehngebot, J. M. Provenzale, C. D. Guy, C. J. Wikstrand, and D. D. Bigner. “Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.” Cancer 91, no. 9 (May 1, 2001): 1809–13.
    Link to Item
  - Vaidyanathan, G., D. J. Affleck, J. Li, P. Welsh, and M. R. Zalutsky. “A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).” Bioconjug Chem 12, no. 3 (May 2001): 428–38. https://doi.org/10.1021/bc0001490.
    Full Text Link to Item
  - Zalutsky, M. R., G. Akabani, H. S. Friedman, I. Cokgor, R. E. Coleman, A. H. Friedman, R. E. McLendon, X. G. Zhao, K. L. Alston, and D. D. Bigner. “Radioimmunotherapy of recurrent glioma patients using alpha-particle emitting astatine-211 labeled chimeric anti-tenascin monoclonal antibody.” Journal of Nuclear Medicine 42, no. 5 (May 1, 2001): 121P-122P.
    Link to Item
  - Meyer, D. E., G. A. Kong, M. W. Dewhirst, M. R. Zalutsky, and A. Chilkoti. “Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia.” Cancer Res 61, no. 4 (February 15, 2001): 1548–54.
    Link to Item
  - Kuan, C. T., C. J. Wikstrand, G. Archer, R. Beers, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.” Int J Cancer 88, no. 6 (December 15, 2000): 962–69. https://doi.org/10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u.
    Full Text Link to Item
  - Cokgor, I., G. Akabani, C. T. Kuan, H. S. Friedman, A. H. Friedman, R. E. Coleman, R. E. McLendon, et al. “Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.” J Clin Oncol 18, no. 22 (November 15, 2000): 3862–72. https://doi.org/10.1200/JCO.2000.18.22.3862.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, C. M. Cavazos, S. P. Johnson, S. Shankar, H. S. Friedman, M. O. Colvin, and M. R. Zalutsky. “Radiolabeled guanine derivatives for the in vivo mapping of O(6)-alkylguanine-DNA alkyltransferase: 6-(4-[(18)F]Fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[(131)I]Iodo-benzyloxy)-9H-purin-2-ylamine.” Bioconjug Chem 11, no. 6 (November 2000): 868–75. https://doi.org/10.1021/bc0000435.
    Full Text Link to Item
  - Bardiès, M., and P. Pihet. “Dosimetry and microdosimetry of targeted radiotherapy.” Curr Pharm Des 6, no. 14 (September 2000): 1469–1502. https://doi.org/10.2174/1381612003399176.
    Full Text Link to Item
  - Zalutsky, M. R., and G. Vaidyanathan. “Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.” Curr Pharm Des 6, no. 14 (September 2000): 1433–55. https://doi.org/10.2174/1381612003399275.
    Full Text Link to Item
  - Foulon, C. F., C. J. Reist, D. D. Bigner, and M. R. Zalutsky. “Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.” Cancer Res 60, no. 16 (August 15, 2000): 4453–60.
    Link to Item
  - Aurlien, E., R. H. Larsen, G. Akabani, D. R. Olsen, M. R. Zalutsky, and O. S. Bruland. “Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.” Int J Radiat Biol 76, no. 8 (August 2000): 1129–41. https://doi.org/10.1080/09553000050111604.
    Full Text Link to Item
  - Xu, F., S. A. Leadon, Y. Yu, C. M. Boyer, K. O’Briant, K. Ward, A. McWatters, et al. “Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.” Clin Cancer Res 6, no. 8 (August 2000): 3334–41.
    Link to Item
  - Akabani, G., R. E. McLendon, D. D. Bigner, and M. R. Zalutsky. “Microdosimetry of alpha-particle-emitting At-211-labelled monoclonal antibody (MAb) using histological images of malignant brain tumors.” Journal of Nuclear Medicine 41, no. 5 (May 1, 2000): 84P-84P.
    Link to Item
  - Vaidyanathan, G., D. Affleck, P. Welsh, A. Srinivasan, M. Schmidt, and M. R. Zalutsky. “Radioiodination and astatination of octreotide by conjugation labeling.” Nucl Med Biol 27, no. 4 (May 2000): 329–37. https://doi.org/10.1016/s0969-8051(00)00098-6.
    Full Text Link to Item
  - Chilkoti, A., D. E. Meyer, G. H. Kong, M. W. Dewhirst, C. Foulon, and M. R. Zalutsky. “Genetically engineered biopolymer conjugate for thermal targeting of anticancer therapeutics.” Abstracts of Papers of the American Chemical Society 219 (March 26, 2000): U453–U453.
    Link to Item
  - Akabani, G., I. Cokgor, R. E. Coleman, D. González Trotter, T. Z. Wong, H. S. Friedman, A. H. Friedman, et al. “Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.” Int J Radiat Oncol Biol Phys 46, no. 4 (March 1, 2000): 947–58. https://doi.org/10.1016/s0360-3016(99)00500-3.
    Full Text Link to Item
  - Meyer, D. E., G. A. Kong, M. W. Dewhirst, C. Foulon, M. R. Zalutsky, and A. Chilkoti. “Genetically engineered polypeptide carrier for thermal targeting of anticancer therapeutics.” American Chemical Society, Polymer Preprints, Division of Polymer Chemistry 41, no. 1 (March 1, 2000): 1020–21.
  - Vaidyanathan, G., D. Affleck, P. Welsh, A. Srinivasan, M. Schmidt, and M. R. Zalutsky. “Radioiodination and astatination of octreotide by conjugation labeling.” Journal of Inorganic Biochemistry 78, no. 3 (February 29, 2000): 329–37.
  - Zalutsky, M. R., F. J. Xu, Y. Yu, C. F. Foulon, X. G. Zhao, S. K. Slade, D. J. Affleck, and R. C. Bast. “Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.” Nucl Med Biol 26, no. 7 (October 1999): 781–90. https://doi.org/10.1016/s0969-8051(99)00060-8.
    Full Text Link to Item
  - Foulon, C. F., D. D. Bigner, and M. R. Zalutsky. “Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.” Bioconjug Chem 10, no. 5 (September 1999): 867–76. https://doi.org/10.1021/bc990040w.
    Full Text Link to Item
  - McLendon, R. E., G. E. Archer, R. H. Larsen, G. Akabani, D. D. Bigner, and M. R. Zalutsky. “Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.” Int J Radiat Oncol Biol Phys 45, no. 2 (September 1, 1999): 491–99. https://doi.org/10.1016/s0360-3016(99)00206-0.
    Full Text Link to Item
  - Zalutsky, M. R., G. Akabani, I. Cokgor, H. S. Friedman, R. E. Coleman, A. H. Friedman, R. E. McLendon, and D. D. Bigner. “Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients.” European Journal of Nuclear Medicine 26, no. 9 (September 1, 1999): 1215–1215.
    Link to Item
  - Larsen, R. H., K. M. Murud, G. Akabani, P. Hoff, O. S. Bruland, and M. R. Zalutsky. “211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.” J Nucl Med 40, no. 7 (July 1999): 1197–1203.
    Link to Item
  - Kuan, C. T., C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “I-125-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.” Clinical Cancer Research 5, no. 6 (June 1, 1999): 1539–49.
    Link to Item
  - Kuan, C. T., C. J. Reist, C. F. Foulon, I. A. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.” Clin Cancer Res 5, no. 6 (June 1999): 1539–49.
    Link to Item
  - Murud, K. M., R. H. Larsen, P. Hoff, and M. R. Zalutsky. “Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates.” Nucl Med Biol 26, no. 4 (May 1999): 397–403. https://doi.org/10.1016/s0969-8051(98)00119-x.
    Full Text Link to Item
  - Reist, C. J., C. F. Foulon, K. Alston, D. D. Bigner, and M. R. Zalutsky. “Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.” Nucl Med Biol 26, no. 4 (May 1999): 405–11. https://doi.org/10.1016/s0969-8051(98)00120-6.
    Full Text Link to Item
  - Akabani, G., C. J. Reist, I. Cokgor, A. H. Friedman, H. S. Friedman, R. E. Coleman, X. G. Zhao, D. D. Bigner, and M. R. Zalutsky. “Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.” J Nucl Med 40, no. 4 (April 1999): 631–38.
    Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Low molecular weight radiopharmaceuticals: Radiohalogenated MIBG and IUdR analogues.” Abstracts of Papers of the American Chemical Society 217 (March 21, 1999): U41–U41.
    Link to Item
  - Foulon, C. F., C. J. Reist, D. D. Bigner, and M. R. Zalutsky. “Radioiodinated D-peptides as prosthetic groups for radiolabeling internalizing antibodies.” Journal of Labelled Compounds and Radiopharmaceuticals 42, no. SUPPL. 1 (January 1, 1999).
  - Kuan, C. T., C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “¹²⁵I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.” Clinical Cancer Research 5, no. 6 (1999): 1539–49.
  - Larsen, R. H., K. M. Murud, G. Akabani, P. Hoff, Ø. S. Bruland, and M. R. Zalutsky. “²¹¹At- and ¹³¹I-labeled bisphosphonates with high in vivo stability and bone accumulation.” Journal of Nuclear Medicine 40, no. 7 (1999): 1197–1203.
  - Olafsen, T., O. Bruland, M. Zalutsky, and I. Sandlie. “Erratum: Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling (Nuclear Medicine and Biology (1995) 22 (765- 771)).” Nuclear Medicine and Biology 26, no. 5 (January 1, 1999): 599. https://doi.org/10.1016/S0969-8051(99)00025-6.
    Full Text
  - Vaidyanathan, G., A. Srinivasan, D. J. Affleck, P. C. Welsh, S. K. Slade, M. A. Schmidt, and M. R. Zalutsky. “Octreotide analogues labeled with radioiodine and astatine-211.” Journal of Labelled Compounds and Radiopharmaceuticals 42, no. SUPPL. 1 (January 1, 1999).
  - Vaidyanathan, G., M. R. Zalutsky, and T. R. DeGrado. “Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine.” Bioconjug Chem 9, no. 6 (November 1998): 758–64. https://doi.org/10.1021/bc980037x.
    Full Text Link to Item
  - Reist, C. J., D. D. Bigner, and M. R. Zalutsky. “Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.” Clin Cancer Res 4, no. 10 (October 1998): 2495–2502.
    Link to Item
  - Hauck, M. L., and M. R. Zalutsky. “The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody.” Clin Cancer Res 4, no. 9 (September 1998): 2071–77.
    Link to Item
  - Walicka, M. A., G. Vaidyanathan, M. R. Zalutsky, S. J. Adelstein, and A. I. Kassis. “Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211.” Radiat Res 150, no. 3 (September 1998): 263–68.
    Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Preparation of 5-[131I]iodo- and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction.” Nucl Med Biol 25, no. 5 (July 1998): 487–96. https://doi.org/10.1016/s0969-8051(98)00004-3.
    Full Text Link to Item
  - Bigner, D. D., M. T. Brown, A. H. Friedman, R. E. Coleman, G. Akabani, H. S. Friedman, W. L. Thorstad, et al. “Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.” J Clin Oncol 16, no. 6 (June 1998): 2202–12. https://doi.org/10.1200/JCO.1998.16.6.2202.
    Full Text Link to Item
  - Cunningham, S. H., R. J. Mairs, T. E. Wheldon, P. C. Welsh, G. Vaidyanathan, and M. R. Zalutsky. “Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.” Br J Cancer 77, no. 12 (June 1998): 2061–68. https://doi.org/10.1038/bjc.1998.348.
    Full Text Open Access Copy Link to Item
  - Berry, C. R., G. Vaidyanathan, P. E. Fisher, M. R. Zalutsky, R. E. Coleman, and T. R. DeGrado. “Myocardial kinetics of meta-[I-131]iodobenzylguanidine in an adriamycin cardiomyopathy rat model.” Journal of Nuclear Medicine 39, no. 5 (May 1, 1998): 47P-47P.
    Link to Item
  - Foulon, C. F., D. D. Bigner, and M. R. Zalutsky. “Pretargeted radioimmunotherapy using anti-tenascin 81C6-streptavidin conjugates and radiolabeled biotin: Preparation of reagents.” Journal of Nuclear Medicine 39, no. 5 (May 1, 1998): 105P-106P.
    Link to Item
  - Larsen, R. H., S. Slade, and M. R. Zalutsky. “Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds.” Nucl Med Biol 25, no. 4 (May 1998): 351–57. https://doi.org/10.1016/s0969-8051(97)00230-8.
    Full Text Link to Item
  - Reist, C. J., D. D. Bigner, and M. R. Zalutsky. “Human IgG(2) constant region enhances the in vivo stability of monoclonal antibody 81C6 compared to its murine parent.” Journal of Nuclear Medicine 39, no. 5 (May 1, 1998): 77P-77P.
    Link to Item
  - Valdyanathan, G., H. S. Friedman, and M. R. Zalutsky. “N.C.A. 5-Iodo-1(2-deoxy,2-fluoro-beta-D-arabinofuranosyl)uracil (FIAU): Tissue uptake in D-54 glioma xenograft mouse model and cytotoxicity to D-247 glioma cells in vitro.” Journal of Nuclear Medicine 39, no. 5 (May 1, 1998): 104P-105P.
    Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Targeted therapy using astatinated radiopharmaceuticals.” Abstracts of Papers of the American Chemical Society 215 (April 2, 1998): U946–U946.
    Link to Item
  - Wikstrand, C. J., C. J. Reist, G. E. Archer, M. R. Zalutsky, and D. D. Bigner. “The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.” J Neurovirol 4, no. 2 (April 1998): 148–58. https://doi.org/10.3109/13550289809114515.
    Full Text Link to Item
  - Hauck, M. L., R. H. Larsen, P. C. Welsh, and M. R. Zalutsky. “Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.” Br J Cancer 77, no. 5 (March 1998): 753–59. https://doi.org/10.1038/bjc.1998.123.
    Full Text Open Access Copy Link to Item
  - Foulon, C. F., K. L. Alston, and M. R. Zalutsky. “Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy.” Nucl Med Biol 25, no. 2 (February 1998): 81–88. https://doi.org/10.1016/s0969-8051(97)00166-2.
    Full Text Link to Item
  - Larsen, R. H., G. Akabani, P. Welsh, and M. R. Zalutsky. “The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.” Radiat Res 149, no. 2 (February 1998): 155–62.
    Link to Item
  - DeGrado, T. R., M. R. Zalutsky, R. E. Coleman, and G. Vaidyanathan. “Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart.” Nucl Med Biol 25, no. 1 (January 1998): 59–64. https://doi.org/10.1016/s0969-8051(97)00158-3.
    Full Text Link to Item
  - Akabani, G., and M. R. Zalutsky. “Microdosimetry of astatine-211 using histological images: application to bone marrow.” Radiat Res 148, no. 6 (December 1997): 599–607.
    Link to Item
  - Reist, C. J., S. K. Batra, C. N. Pegram, D. D. Bigner, and M. R. Zalutsky. “In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.” Nucl Med Biol 24, no. 7 (October 1997): 639–47. https://doi.org/10.1016/s0969-8051(97)00080-2.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate.” Bioconjug Chem 8, no. 5 (September 1997): 724–29. https://doi.org/10.1021/bc9700502.
    Full Text Link to Item
  - Larsen, R. H., G. Vaidyanathan, and M. R. Zalutsky. “Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.” Int J Radiat Biol 72, no. 1 (July 1997): 79–90. https://doi.org/10.1080/095530097143563.
    Full Text Link to Item
  - Vaidyanathan, G., X. -. G. Zhao, R. H. Larsen, and M. R. Zalutsky. “3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.” British Journal of Cancer 76, no. 2 (July 1997): 226–33. https://doi.org/10.1038/bjc.1997.366.
    Full Text
  - Vaidyanathan, Ganesan, and Michael R. Zalutsky. “A New Route to Guanidines from Bromoalkanes.” The Journal of Organic Chemistry 62, no. 14 (July 1, 1997): 4867–69. https://doi.org/10.1021/jo9704164.
    Full Text
  - Xu, F. J., Y. H. Yu, D. S. Bae, X. G. Zhao, S. K. Slade, C. M. Boyer, R. C. Bast, and M. R. Zalutsky. “Radioiodinated antibody targeting of the HER-2/neu oncoprotein.” Nucl Med Biol 24, no. 5 (July 1997): 451–59. https://doi.org/10.1016/s0969-8051(97)00065-6.
    Full Text Link to Item
  - Zalutsky, M. R. “Growth factor receptors as molecular targets for cancer diagnosis and therapy.” Q J Nucl Med 41, no. 2 (June 1997): 71–77.
    Link to Item
  - Akabani, G., W. L. Thorstad, M. T. Brown, R. E. Coleman, M. R. Zalutsky, and D. D. Bigner. “Dosimetry methods for patients with malignant CNS tumors treated with I-131 81C6 via surgically created cystic resection cavity.” Journal of Nuclear Medicine 38, no. 5 (May 1, 1997): 395–395.
    Link to Item
  - Akabani, G., and M. R. Zalutsky. “Microdosimetry and small-scale dosimetry of At-211 in bone marrow: An analysis based on histological imaging.” Journal of Nuclear Medicine 38, no. 5 (May 1, 1997): 963–963.
    Link to Item
  - DeGrado, T. R., M. R. Zalutsky, and G. Vaidyanathan. “Mechanisms of uptake in isolated rat heart of potential radiotherapeutic agent [At-211]meta-astatobenzylguanidine (MABG).” Journal of Nuclear Medicine 38, no. 5 (May 1, 1997): 106–106.
    Link to Item
  - Hauck, M. L., D. O. Coffin, R. K. Dodge, M. W. Dewhirst, J. B. Mitchell, and M. R. Zalutsky. “A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure.” Int J Hyperthermia 13, no. 3 (May 1997): 307–16. https://doi.org/10.3109/02656739709023538.
    Full Text Link to Item
  - Kassis, A. I., M. A. Walicka, G. Vaidyanathan, M. R. Zalutsky, and S. J. Adelstein. “Survival and DNA damage in V79 cells exposed to the alpha emitters 5-[At-211]astato-2'-deoxy-uridine and [At-211]astatide.” Journal of Nuclear Medicine 38, no. 5 (May 1, 1997): 964–964.
    Link to Item
  - Reist, C. J., C. F. Foulon, D. D. Bigner, and M. R. Zalutsky. “A method for labeling internalizing antibodies with astatine-211.” Journal of Nuclear Medicine 38, no. 5 (May 1, 1997): 15–15.
    Link to Item
  - Reist, C. J., G. E. Archer, C. J. Wikstrand, D. D. Bigner, and M. R. Zalutsky. “Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.” Cancer Res 57, no. 8 (April 15, 1997): 1510–15.
    Link to Item
  - Zalutsky, M. R., M. G. Stabin, R. H. Larsen, and D. D. Bigner. “Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.” Nucl Med Biol 24, no. 3 (April 1997): 255–61. https://doi.org/10.1016/s0969-8051(97)00060-7.
    Full Text Link to Item
  - Foulon, C. F., K. L. Alston, and M. R. Zalutsky. “Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability.” Bioconjug Chem 8, no. 2 (March 1997): 179–86. https://doi.org/10.1021/bc970006m.
    Full Text Link to Item
  - Foulon, C. F., B. W. Schoultz, and M. R. Zalutsky. “Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide.” Nucl Med Biol 24, no. 2 (February 1997): 135–43. https://doi.org/10.1016/s0969-8051(96)00185-0.
    Full Text Link to Item
  - Vaidyanathan, G., X. G. Zhao, D. K. Strickland, and M. R. Zalutsky. “No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.” J Nucl Med 38, no. 2 (February 1997): 330–34.
    Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue.” Nucl Med Biol 24, no. 2 (February 1997): 171–78. https://doi.org/10.1016/s0969-8051(96)00211-9.
    Full Text Link to Item
  - Hauck, M. L., M. W. Dewhirst, D. D. Bigner, and M. R. Zalutsky. “Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model.” Clin Cancer Res 3, no. 1 (January 1997): 63–70.
    Link to Item
  - Vaidyanathan, G., X. G. Zhao, R. H. Larsen, and M. R. Zalutsky. “3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.” Br J Cancer 76, no. 2 (1997): 226–33. https://doi.org/10.1038/bjc.1997.366.
    Full Text Open Access Copy Link to Item
  - Vaidyanathan, G., X. G. Zhao, R. H. Larsen, and M. R. Zalutsky. “3-[²¹¹At]astato-4-fluorobenzylguanidine: A potential therapeutic agent with prolonged retention by neuroblastoma cells.” British Journal of Cancer 76, no. 2 (1997): 226–33.
  - Berry, C. R., P. K. Garg, M. R. Zalutsky, R. E. Coleman, and T. R. DeGrado. “Uptake and retention kinetics of para-fluorine-18-fluorobenzylguanidine in isolated rat heart.” J Nucl Med 37, no. 12 (December 1996): 2011–16.
    Link to Item
  - Reist, C. J., P. K. Garg, K. L. Alston, D. D. Bigner, and M. R. Zalutsky. “Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.” Cancer Res 56, no. 21 (November 1, 1996): 4970–77.
    Link to Item
  - Reist, C. J., P. K. Garg, K. L. Alston, D. D. Bigner, and M. R. Zalutsky. “A method for the radiohalogenation of internalizing antibodies.” Journal of Nuclear Medicine 37, no. 10 (October 1, 1996): 1825–1825.
    Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Targeted therapy using alpha emitters.” Phys Med Biol 41, no. 10 (October 1996): 1915–31. https://doi.org/10.1088/0031-9155/41/10/005.
    Full Text Link to Item
  - Vaidyanathan, G., H. S. Friedman, S. T. Keir, and M. R. Zalutsky. “Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.” Nucl Med Biol 23, no. 6 (August 1996): 851–56. https://doi.org/10.1016/0969-8051(96)00115-1.
    Full Text Link to Item
  - Brown, M. T., R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, R. Reiman, G. J. Felsberg, et al. “Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.” Clin Cancer Res 2, no. 6 (June 1996): 963–72.
    Link to Item
  - DeGrado, T. R., M. R. Zalutsky, R. E. Coleman, and G. Vaidyanathan. “Effects of specific activity on uptake and retention of metaiodobenzylguanidine (MIBG) in the heart: Revisited.” Journal of Nuclear Medicine 37, no. 5 (May 1, 1996): 701–701.
    Link to Item
  - Foulon, C. F., R. H. Larsen, and M. R. Zalutsky. “Preparation and binding properties of an astatine-211 labeled biotin conjugate.” Journal of Nuclear Medicine 37, no. 5 (May 1, 1996): 900–900.
    Link to Item
  - Garg, P. K., C. R. Berry, R. T. DeGrado, F. Nutter, E. Breitschwerdt, M. R. Zalutsky, and R. E. Coleman. “PET imaging of pheochromocytoma (PHEO) in dogs using PARA [F-18]fluorobenzylguanidine (PFBG).” Journal of Nuclear Medicine 37, no. 5 (May 1, 1996): 915–915.
    Link to Item
  - Hauck, M. L., M. W. Dewhirst, and M. R. Zalutsky. “The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody.” Nucl Med Biol 23, no. 4 (May 1996): 551–57. https://doi.org/10.1016/0969-8051(96)00039-x.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, P. C. Welsh, S. A. Slade, K. L. Alston, and M. R. Zalutsky. “Fluorine-18 labeling of [Nle(4),D-Phe(7)]-alpha-MSH, an alpha-melanocyte stimulating hormone (alpha-MSH) analogue.” Journal of Nuclear Medicine 37, no. 5 (May 1, 1996): 875–875.
    Link to Item
  - Vaidyanathan, G., H. S. Friedman, S. T. Keir, and M. R. Zalutsky. “Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.” Br J Cancer 73, no. 10 (May 1996): 1171–77. https://doi.org/10.1038/bjc.1996.226.
    Full Text Open Access Copy Link to Item
  - Vaidyanathan, G., H. S. Friedman, S. T. Keir, and M. R. Zalutsky. “Meta-[At-211]astatobenzylguanidine (MABG): In vivo evaluation in an athymic mouse human neuroblastoma xenograft model.” Journal of Nuclear Medicine 37, no. 5 (May 1, 1996): 236–236.
    Link to Item
  - Zalutsky, M. R., G. E. Archer, P. K. Garg, S. K. Batra, and D. D. Bigner. “Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.” Nucl Med Biol 23, no. 4 (May 1996): 449–58. https://doi.org/10.1016/0969-8051(96)00021-2.
    Full Text Link to Item
  - McLendon, R. E., G. E. Archer, P. K. Garg, D. D. Bigner, and M. R. Zalutsky. “Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis.” Int J Radiat Oncol Biol Phys 35, no. 1 (April 1, 1996): 69–80. https://doi.org/10.1016/s0360-3016(96)85013-9.
    Full Text Link to Item
  - Vaidyanathan, G., R. H. Larsen, and M. R. Zalutsky. “5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.” Cancer Res 56, no. 6 (March 15, 1996): 1204–9.
    Link to Item
  - Vaidyanathan, G., R. H. Larsen, and M. R. Zalutsky. “Particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.” Cancer Research 56, no. 6 (March 15, 1996): 1204–9.
  - Vaidyanathan, G., R. H. Larsen, and M. R. Zalutsky. “5-[At-211]astato-2'-deoxyuridine, an alpha-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.” Cancer Research 56, no. 6 (March 15, 1996): 1204–9.
    Link to Item
  - Berry, C. R., P. K. Garg, T. R. DeGrado, P. Hellyer, W. Weber, S. Garg, B. Hansen, M. R. Zalutsky, and R. E. Coleman. “Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model.” J Nucl Cardiol 3, no. 2 (March 1996): 119–29. https://doi.org/10.1016/s1071-3581(96)90004-5.
    Full Text Link to Item
  - Garg, P. K., K. L. Alston, P. C. Welsh, and M. R. Zalutsky. “Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate.” Bioconjug Chem 7, no. 2 (March 1996): 233–39. https://doi.org/10.1021/bc960001+.
    Full Text Link to Item
  - Larsen, R. H., B. W. Wieland, and M. R. Zalutsky. “Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction.” Appl Radiat Isot 47, no. 2 (February 1996): 135–43. https://doi.org/10.1016/0969-8043(95)00285-5.
    Full Text Link to Item
  - Garg, P. K., K. L. Alston, P. C. Welsh, and M. R. Zalutsky. “Preliminary Evaluation of Radioiodinated Alpha-melanocyte Stimulating Hormone (a-MSH) and its Analogue Using N-succinimidyl 3-iodobenzoate and Iodogen Methods.” Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 496.
  - Garg, P. K., K. L. Alston, and M. R. Zalutsky. “Catabolism of Label from an F(ab')2 Fragment Radioiodinated Using N-Succinimidyl 3-iodobenzoate and Iodogen Methods.” Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 539.
  - Larsen, R. H., B. W. Wieland, and M. R. Zalutsky. “Evaluation of an internal cyclotron target for the production of ²¹¹at via the ²⁰⁹Bi (α,2n)²¹¹at reaction.” Applied Radiation and Isotopes 47, no. 2 (1996): 135–43.
  - Olafsen, T., O. S. Bruland, M. R. Zalutsky, and I. Sandlie. “Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling.” Acta Oncol 35, no. 3 (1996): 297–301. https://doi.org/10.3109/02841869609101644.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, S. A. Slade, and M. R. Zalutsky. “Labeling of Monoclonal Antibodies (MAbs) with N-Succinimidyl 3-hydroxy-4-[131I]iodobenzoate (mSHIB).” Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 536.
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine.” Bioconjug Chem 7, no. 1 (January 1996): 102–7. https://doi.org/10.1021/bc950078i.
    Full Text Link to Item
  - Zalutsky, M. R., J. M. Schuster, P. K. Garg, G. E. Archer, M. W. Dewhirst, and D. D. Bigner. “Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.” Recent Results Cancer Res 141 (1996): 101–22. https://doi.org/10.1007/978-3-642-79952-5_7.
    Full Text Link to Item
  - Zalutsky, M. R., and D. D. Bigner. “Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.” Acta Oncol 35, no. 3 (1996): 373–79. https://doi.org/10.3109/02841869609101654.
    Full Text Link to Item
  - Smellie, W. J., C. J. Dean, N. P. Sacks, M. R. Zalutsky, P. K. Garg, P. Carnochan, and S. A. Eccles. “Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods.” Cancer Res 55, no. 23 Suppl (December 1, 1995): 5842s-5846s.
    Link to Item
  - Reist, C. J., G. E. Archer, S. N. Kurpad, C. J. Wikstrand, G. Vaidyanathan, M. C. Willingham, D. K. Moscatello, A. J. Wong, D. D. Bigner, and M. R. Zalutsky. “Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.” Cancer Res 55, no. 19 (October 1, 1995): 4375–82.
    Link to Item
  - Olafsen, T., O. S. Bruland, M. R. Zalutsky, and I. Sandlie. “Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling.” Nucl Med Biol 22, no. 6 (August 1995): 765–71. https://doi.org/10.1016/0969-8051(95)00014-o.
    Full Text Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Fluorine-18 labeled chemotactic peptides: a potential approach for the PET imaging of bacterial infection.” Nucl Med Biol 22, no. 6 (August 1995): 759–64. https://doi.org/10.1016/0969-8051(95)00028-v.
    Full Text Link to Item
  - Wikstrand, C. J., L. P. Hale, S. K. Batra, M. L. Hill, P. A. Humphrey, S. N. Kurpad, R. E. McLendon, D. Moscatello, C. N. Pegram, and C. J. Reist. “Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.” Cancer Res 55, no. 14 (July 15, 1995): 3140–48.
    Link to Item
  - Garg, P. K., K. L. Alston, and M. R. Zalutsky. “Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods.” Bioconjug Chem 6, no. 4 (July 1995): 493–501. https://doi.org/10.1021/bc00034a020.
    Full Text Link to Item
  - Mairs, R. J., and M. R. Zalutsky. “New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.” Br J Cancer 72, no. 1 (July 1995): 250. https://doi.org/10.1038/bjc.1995.312.
    Full Text Open Access Copy Link to Item
  - Garg, P. K., C. S. John, and M. R. Zalutsky. “Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide.” Nucl Med Biol 22, no. 4 (May 1995): 467–73. https://doi.org/10.1016/0969-8051(94)00134-6.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.” J Nucl Med 36, no. 4 (April 1995): 644–50.
    Link to Item
  - Bigner, D. D., M. Brown, R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, S. H. Bigner, X. G. Zhao, C. J. Wikstrand, and C. N. Pegram. “Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.” J Neurooncol 24, no. 1 (1995): 109–22. https://doi.org/10.1007/BF01052668.
    Full Text Link to Item
  - Degrado, T. R., M. R. Zalutsky, and G. Vaidyanathan. “Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart.” Nucl Med Biol 22, no. 1 (January 1995): 1–12. https://doi.org/10.1016/0969-8051(94)00084-w.
    Full Text Link to Item
  - Johnson, E. L., T. G. Turkington, R. J. Jaszczak, D. R. Gilland, G. Vaidyanathan, K. L. Greer, R. E. Coleman, and M. R. Zalutsky. “Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models.” Nucl Med Biol 22, no. 1 (January 1995): 45–54. https://doi.org/10.1016/0969-8051(94)00077-w.
    Full Text Link to Item
  - Mairs, R. J., J. Russell, S. Cunningham, J. A. O’Donoghue, M. N. Gaze, J. Owens, G. Vaidyanathan, and M. R. Zalutsky. “Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.” Eur J Cancer 31A, no. 4 (1995): 576–81. https://doi.org/10.1016/0959-8049(95)00052-k.
    Full Text Link to Item
  - Schuster, J. M., M. R. Zalutsky, M. A. Noska, R. Dodge, H. S. Friedman, D. D. Bigner, and M. W. Dewhirst. “Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues.” Int J Hyperthermia 11, no. 1 (January 1995): 59–72. https://doi.org/10.3109/02656739509004948.
    Full Text Link to Item
  - Strickland, D. K., G. Vaidyanathan, H. S. Friedman, and M. R. Zalutsky. “Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.” J Neurooncol 25, no. 1 (1995): 9–17. https://doi.org/10.1007/BF01054718.
    Full Text Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation.” Nucl Med Biol 22, no. 1 (January 1995): 61–64. https://doi.org/10.1016/0969-8051(94)00078-x.
    Full Text Link to Item
  - Strickland, D. K., G. Vaidyanathan, and M. R. Zalutsky. “Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.” Cancer Res 54, no. 20 (October 15, 1994): 5414–19.
    Link to Item
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.” J Med Chem 37, no. 21 (October 14, 1994): 3655–62. https://doi.org/10.1021/jm00047a022.
    Full Text Link to Item
  - Page, R. L., P. K. Garg, G. Vaidyanathan, and M. R. Zalutsky. “Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab')2 fragment in normal dogs.” Nucl Med Biol 21, no. 7 (October 1994): 911–19. https://doi.org/10.1016/0969-8051(94)90079-5.
    Full Text Link to Item
  - Page, R. L., P. K. Garg, S. Garg, G. E. Archer, O. S. Bruland, and M. R. Zalutsky. “PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment.” J Nucl Med 35, no. 9 (September 1994): 1506–13.
    Link to Item
  - Zalutsky, M. R., R. E. McLendon, P. K. Garg, G. E. Archer, J. M. Schuster, and D. D. Bigner. “Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.” Cancer Res 54, no. 17 (September 1, 1994): 4719–25.
    Link to Item
  - He, X., G. E. Archer, C. J. Wikstrand, S. L. Morrison, M. R. Zalutsky, D. D. Bigner, and S. K. Batra. “Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.” J Neuroimmunol 52, no. 2 (July 1994): 127–37. https://doi.org/10.1016/0165-5728(94)90106-6.
    Full Text Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment.” Bioconjug Chem 5, no. 4 (July 1994): 352–56. https://doi.org/10.1021/bc00028a012.
    Full Text Link to Item
  - Vaidyanathan, G., D. K. Strickland, and M. R. Zalutsky. “Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.” Int J Cancer 57, no. 6 (June 15, 1994): 908–13. https://doi.org/10.1002/ijc.2910570622.
    Full Text Link to Item
  - BERRY, C. R., P. K. GARG, T. R. DEGRADO, S. GARG, P. HELLYER, W. J. WEBER, R. E. COLEMAN, and M. R. ZALUTSKY. “PARA[F-18] FLUOROBENZYLGUANIDINE (PFBG) KINETICS IN A CANINE CORONARY-ARTERY OCCLUSION MODEL.” Journal of Nuclear Medicine 35, no. 5 (May 1, 1994): P157–P157.
    Link to Item
  - DEGRADO, T. R., M. R. ZALUTSKY, D. J. AFFLECK, and G. VAIDYANATHAN. “MECHANISTIC STUDIES OF METAIODOBENZYLGUANIDINE (METAIODOBENZYLGUANIDINE) UPTAKE AND RETENTION IN ISOLATED RAT-HEART.” Journal of Nuclear Medicine 35, no. 5 (May 1, 1994): P57–P57.
    Link to Item
  - GARG, P. K., C. R. BERRY, T. R. DEGRADO, S. GARG, P. HELLYER, R. E. COLEMAN, and M. R. ZALUTSKY. “MYOCARDIAL AND ADRENAL UPTAKE OF PARA [F-18] FLUOROBENZYLGUANIDINE (PFBG) IN THE DOG.” Journal of Nuclear Medicine 35, no. 5 (May 1, 1994): P255–P255.
    Link to Item
  - JANG, S., T. TURKINGTON, R. J. JASZCZAK, J. LI, K. L. GREER, M. R. ZALUTSKY, and R. E. COLEMAN. “QUANTITATIVE MEASUREMENTS FOR SMALL ORGANS OF MONKEY.” Journal of Nuclear Medicine 35, no. 5 (May 1, 1994): P179–P179.
    Link to Item
  - JOHNSON, E. L., T. G. TURKINGTON, R. J. JASZCZAK, M. R. ZALUTSKY, D. R. GILLAND, G. VAIDYANATHAN, K. L. GREER, and R. E. COLEMAN. “QUANTITATIVE IMAGING OF AT-211 RADIOTHERAPEUTIC AGENTS IN SMALL VOLUMES.” Journal of Nuclear Medicine 35, no. 5 (May 1, 1994): P180–P180.
    Link to Item
  - VAIDYANATHAN, G., D. J. AFFLECK, S. A. SLADE, P. C. WELSH, and M. R. ZALUTSKY. “SYNTHESIS AND PRELIMINARY EVALUATION OF 4-[F-18]FLUORO-3-IODOBENZYLGUANIDINE (FIBG) - A METAIODOBENZYLGUANIDINE ANALOG FOR PET.” Journal of Nuclear Medicine 35, no. 5 (May 1, 1994): P248–P248.
    Link to Item
  - Batra, S. K., M. L. Niswonger, C. J. Wikstrand, C. N. Pegram, M. R. Zalutsky, S. L. Morrison, and D. D. Bigner. “Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.” Hybridoma 13, no. 2 (April 1994): 87–97. https://doi.org/10.1089/hyb.1994.13.87.
    Full Text Link to Item
  - Mairs, R. J., M. N. Gaze, D. G. Watson, G. G. Skellern, P. Constable, K. McKellar, J. Owens, G. Vaidyanathan, and M. R. Zalutsky. “Carrier-free 131I-meta-iodobenzylguanidine: comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine.” Nucl Med Commun 15, no. 4 (April 1994): 268–74. https://doi.org/10.1097/00006231-199404000-00157.
    Full Text Link to Item
  - Jaszczak, R. J., J. Li, H. Wang, M. R. Zalutsky, and R. E. Coleman. “Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT.” Phys Med Biol 39, no. 3 (March 1994): 425–37. https://doi.org/10.1088/0031-9155/39/3/010.
    Full Text Link to Item
  - Garg, P. K., S. Garg, X. G. Zhao, P. C. Welsh, and M. R. Zalutsky. “Catabolism of label from Mel-14 F(ab')2 fragment radiohalogenated using N-succinimidyl 3-halobenzoates.” Journal of Labelled Compounds and Radiopharmaceuticals 35 (January 1, 1994): 310–12.
  - Garg, P. K., S. Garg, and M. R. Zalutsky. “Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidine.” Nucl Med Biol 21, no. 1 (January 1994): 97–103. https://doi.org/10.1016/0969-8051(94)90135-x.
    Full Text Link to Item
  - Gaze, M. N., R. J. Mairs, G. Vaidyanathan, and M. R. Zalutsky. “Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma.” Prog Clin Biol Res 385 (1994): 347–53.
    Link to Item
  - Vaidyanathan, G., D. A. Affleck, P. Welsh, and M. R. Zalutsky. “Fluorine-18 labeled chemotactic peptide: A potential agent for the PET imaging of focal infection.” Journal of Labelled Compounds and Radiopharmaceuticals 35 (January 1, 1994): 365–67.
  - Vaidyanathan, G., D. Affleck, and M. R. Zalutsky. “Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments.” Nucl Med Biol 21, no. 1 (January 1994): 105–10. https://doi.org/10.1016/0969-8051(94)90136-8.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “(4-[¹⁸F]fluoro-3-iodobenzyl)guanidine, a potential mibg analogue for positron emission tomography.” Journal of Medicinal Chemistry 37, no. 21 (1994): 3655–62.
  - Vaidyanathan, G., D. K. Strickland, D. A. Affleck, P. Welsh, and M. R. Zalutsky. “Meta-[²¹¹At]astatobenzylguanidine: Further validation of in vitro and in vivo uptake mechanisms.” Journal of Labelled Compounds and Radiopharmaceuticals 35 (1994): 589–91.
  - DEGRADO, T. R., M. R. ZALUTSKY, D. J. AFFLECK, and G. VAIDYANATHAN. “UPTAKE MECHANISMS OF I-123 METAIODOBENZYLGUANIDINE (METAIODOBENZYLGUANIDINE) IN ISOLATED RAT-HEART.” Circulation 88, no. 4 (October 1, 1993): 355–355.
    Link to Item
  - Garg, S., P. K. Garg, X. G. Zhao, H. S. Friedman, D. D. Bigner, and M. R. Zalutsky. “Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate.” Nucl Med Biol 20, no. 7 (October 1993): 835–42. https://doi.org/10.1016/0969-8051(93)90149-o.
    Full Text Link to Item
  - Turkington, T. G., M. R. Zalutsky, R. J. Jaszczak, P. K. Garg, G. Vaidyanathan, and R. E. Coleman. “Measuring astatine-211 distributions with SPECT.” Phys Med Biol 38, no. 8 (August 1993): 1121–30. https://doi.org/10.1088/0031-9155/38/8/010.
    Full Text Link to Item
  - Schold, S. C., M. R. Zalutsky, R. E. Coleman, M. J. Glantz, A. H. Friedman, R. J. Jaszczak, S. H. Bigner, and D. D. Bigner. “Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.” Invest Radiol 28, no. 6 (June 1993): 488–96.
    Link to Item
  - GARG, P. K., S. GARG, R. E. COLEMAN, and M. R. ZALUTSKY. “PARA[F-18]FLUOROBENZYLGUANIDINE (PFBG) - A POTENTIAL TRACER FOR IMAGING HEART AND TUMOR USING PET.” Journal of Nuclear Medicine 34, no. 5 (May 1, 1993): P79–P79.
    Link to Item
  - GARG, S., P. K. GARG, and M. R. ZALUTSKY. “LABELING MONOCLONAL-ANTIBODIES (MABS) WITH AT-211 USING N-SUCCINIMIDYL 5-[AT-211]ASTATO-3-PYRIDINECARBOXYLATE (SAPC).” Journal of Nuclear Medicine 34, no. 5 (May 1, 1993): P99–100.
    Link to Item
  - Garg, P. K., S. Garg, and M. R. Zalutsky. “N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies.” Nucl Med Biol 20, no. 4 (May 1993): 379–87. https://doi.org/10.1016/0969-8051(93)90067-5.
    Full Text Link to Item
  - JASZCZAK, R. J., J. LI, H. WANG, M. R. ZALUTSKY, and R. E. COLEMAN. “PINHOLE COLLIMATION FOR ULTRA-HIGH-RESOLUTION, SMALL-FIELD-OF-VIEW SPECT STUDIES.” Journal of Nuclear Medicine 34, no. 5 (May 1, 1993): P10–P10.
    Link to Item
  - PAGE, R. L., P. K. GARG, S. GARG, O. S. BRULAND, and M. R. ZALUTSKY. “IMAGING OSTEOSARCOMA IN DOGS USING F-18 LABELED TP-3 MONOCLONAL-ANTIBODY (MAB) FRAGMENT AND PET.” Journal of Nuclear Medicine 34, no. 5 (May 1, 1993): P216–P216.
    Link to Item
  - TURKINGTON, T. G., M. R. ZALUTSKY, R. J. JASZCZAK, P. GARG, G. VAIDYANATHAN, and R. E. COLEMAN. “MEASURING ASTATINE-211 DISTRIBUTIONS WITH SPECT.” Journal of Nuclear Medicine 34, no. 5 (May 1, 1993): P191–P191.
    Link to Item
  - VAIDYANATHAN, G., C. HARRISON, P. WELSH, D. AFFLECK, and M. R. ZALUTSKY. “INVITRO CYTOTOXICITY OF M-[AT-211]ASTATOBENZYLGUANIDINE (MABG).” Journal of Nuclear Medicine 34, no. 5 (May 1, 1993): P218–P218.
    Link to Item
  - BATRA, S. K., M. NISWONGER, C. J. WIKSTRAND, M. R. ZALUTSKY, S. L. MORRISON, and D. D. BIGNER. “GENERATION AND CHARACTERIZATION OF MOUSE-HUMAN CHIMERIC MEL-14 ANTIBODY.” Journal of Immunology 150, no. 8 (April 15, 1993): A150–A150.
    Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.” Appl Radiat Isot 44, no. 3 (March 1993): 621–28. https://doi.org/10.1016/0969-8043(93)90179-e.
    Full Text Link to Item
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate.” Bioconjug Chem 4, no. 1 (January 1993): 78–84. https://doi.org/10.1021/bc00019a011.
    Full Text Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.” Bioconjug Chem 3, no. 6 (November 1992): 499–503. https://doi.org/10.1021/bc00018a006.
    Full Text Link to Item
  - Garg, P. K., S. Garg, D. D. Bigner, and M. R. Zalutsky. “Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model.” Cancer Res 52, no. 18 (September 15, 1992): 5054–60.
    Link to Item
  - Moseley, R. P., V. Papanastassiou, M. R. Zalutsky, R. D. Ashpole, S. Evans, D. D. Bigner, and J. T. Kemshead. “Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.” Int J Cancer 52, no. 1 (August 19, 1992): 38–43. https://doi.org/10.1002/ijc.2910520109.
    Full Text Link to Item
  - Vaidyanathan, G., D. D. Bigner, and M. R. Zalutsky. “Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography.” J Nucl Med 33, no. 8 (August 1992): 1535–41.
    Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate.” Int J Rad Appl Instrum B 19, no. 3 (April 1992): 275–81. https://doi.org/10.1016/0883-2897(92)90111-b.
    Full Text Link to Item
  - Zalutsky, M. R., P. K. Garg, S. H. Johnson, H. Utsunomiya, and R. E. Coleman. “Fluorine-18-antimyosin monoclonal antibody fragments: preliminary investigations in a canine myocardial infarct model.” J Nucl Med 33, no. 4 (April 1992): 575–80.
    Link to Item
  - Garg, P. K., S. Garg, W. G. Degraff, M. R. Zalutsky, and J. B. Mitchell. “4-Fluorobenzylamine and phenylalanine methyl ester conjugates of 2-nitroimidazole: evaluation as hypoxic cell radiosensitizers.” Int J Radiat Oncol Biol Phys 22, no. 3 (1992): 593–96. https://doi.org/10.1016/0360-3016(92)90884-k.
    Full Text Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “1-(m-[²¹¹At]astatobenzyl)guanidine: Synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.” Bioconjugate Chemistry 3, no. 6 (1992): 499–503.
  - Schuster, J. M., P. K. Garg, D. D. Bigner, and M. R. Zalutsky. “Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.” Cancer Res 51, no. 16 (August 15, 1991): 4164–69.
    Link to Item
  - Garg, S., P. K. Garg, D. D. Bigner, and M. R. Zalutsky. “Radioiodination and astatination of monoclonal antibodies using heterocyclic acylation agents.” Journal of Labelled Compounds and Radiopharmaceuticals 30 (April 5, 1991).
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “Aromatic acylation reagents for use in the radioiodination of proteins.” Journal of Labelled Compounds and Radiopharmaceuticals 30 (April 5, 1991).
  - Garg, P. K., S. Garg, and M. R. Zalutsky. “Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity.” Bioconjug Chem 2, no. 1 (January 1991): 44–49. https://doi.org/10.1021/bc00007a008.
    Full Text Link to Item
  - Garg, S., P. K. Garg, and M. R. Zalutsky. “N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination.” Bioconjug Chem 2, no. 1 (January 1991): 50–56. https://doi.org/10.1021/bc00007a009.
    Full Text Link to Item
  - Worlock, A. J., M. R. Zalutsky, and R. S. Metzgar. “Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1.” Cancer Res 50, no. 22 (November 15, 1990): 7246–51.
    Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates.” Bioconjug Chem 1, no. 6 (November 1990): 387–93. https://doi.org/10.1021/bc00006a004.
    Full Text Link to Item
  - Moseley, R. P., A. G. Davies, R. B. Richardson, M. Zalutsky, S. Carrell, J. Fabre, N. Slack, J. Bullimore, B. Pizer, and V. Papanastassiou. “Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.” Br J Cancer 62, no. 4 (October 1990): 637–42. https://doi.org/10.1038/bjc.1990.345.
    Full Text Link to Item
  - Vaidyanathan, G., and M. R. Zalutsky. “Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents.” Bioconjug Chem 1, no. 4 (July 1990): 269–73. https://doi.org/10.1021/bc00004a007.
    Full Text Link to Item
  - Zalutsky, M. R., R. P. Moseley, J. C. Benjamin, E. V. Colapinto, G. N. Fuller, H. P. Coakham, and D. D. Bigner. “Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.” Cancer Res 50, no. 13 (July 1, 1990): 4105–10.
    Link to Item
  - Garg, P. K., C. L. Harrison, and M. R. Zalutsky. “Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment.” Cancer Res 50, no. 12 (June 15, 1990): 3514–20.
    Link to Item
  - Humphrey, P. A., A. J. Wong, B. Vogelstein, M. R. Zalutsky, G. N. Fuller, G. E. Archer, H. S. Friedman, M. M. Kwatra, S. H. Bigner, and D. D. Bigner. “Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.” Proc Natl Acad Sci U S A 87, no. 11 (June 1990): 4207–11. https://doi.org/10.1073/pnas.87.11.4207.
    Full Text Link to Item
  - GARG, P. K., G. VAIDYANATHAN, S. GARG, and M. R. ZALUTSKY. “RADIOIODINATION AND ASTATINATION OF MONOCLONAL-ANTIBODIES.” Abstracts of Papers of the American Chemical Society 199 (April 22, 1990): 16-NUCL.
    Link to Item
  - “National Cancer Institute Workshop statement. Advances in clinical imaging using positron emission tomography, September 14-16, 1988. The Workshop Panel.” Arch Intern Med 150, no. 4 (April 1990): 735–39. https://doi.org/10.1001/archinte.150.4.735.
    Full Text Link to Item
  - Colapinto, E. V., M. R. Zalutsky, G. E. Archer, M. A. Noska, H. S. Friedman, S. Carrel, and D. D. Bigner. “Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.” Cancer Res 50, no. 6 (March 15, 1990): 1822–27.
    Link to Item
  - Cope, D. A., M. W. Dewhirst, H. S. Friedman, D. D. Bigner, and M. R. Zalutsky. “Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.” Cancer Res 50, no. 6 (March 15, 1990): 1803–9.
    Link to Item
  - Venkatesan, P. P., S. Shortkroff, M. R. Zalutsky, and C. B. Sledge. “Rhenium heptasulfide: a potential carrier system for radiation synovectomy.” Int J Rad Appl Instrum B 17, no. 4 (1990): 357–62. https://doi.org/10.1016/0883-2897(90)90101-6.
    Full Text Link to Item
  - Zalutsky, M. R., P. K. Garg, and A. S. Narula. “Labeling monoclonal antibodies with halogen nuclides.” Acta Radiol Suppl 374 (1990): 141–45.
    Link to Item
  - Zalutsky, M. R., M. A. Noska, E. V. Colapinto, P. K. Garg, and D. D. Bigner. “Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.” Cancer Res 49, no. 20 (October 15, 1989): 5543–49.
    Link to Item
  - Zalutsky, M. R., P. K. Garg, H. S. Friedman, and D. D. Bigner. “Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.” Proc Natl Acad Sci U S A 86, no. 18 (September 1989): 7149–53. https://doi.org/10.1073/pnas.86.18.7149.
    Full Text Link to Item
  - Zalutsky, M. R., R. P. Moseley, H. B. Coakham, R. E. Coleman, and D. D. Bigner. “Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.” Cancer Res 49, no. 10 (May 15, 1989): 2807–13.
    Link to Item
  - ZALUTSKY, M. R., and P. K. GARG. “RADIOHALOGENATION OF ANTIBODIES.” Abstracts of Papers of the American Chemical Society 197 (April 9, 1989): 84-NUCL.
    Link to Item
  - Garg, P. K., G. E. Archer, D. D. Bigner, and M. R. Zalutsky. “Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling.” Int J Rad Appl Instrum A 40, no. 6 (1989): 485–90. https://doi.org/10.1016/0883-2889(89)90131-7.
    Full Text Link to Item
  - Garg, P. K., S. K. Slade, C. L. Harrison, and M. R. Zalutsky. “Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability.” Int J Rad Appl Instrum B 16, no. 7 (1989): 669–73. https://doi.org/10.1016/0883-2897(89)90136-0.
    Full Text Link to Item
  - Narula, A. S., and M. R. Zalutsky. “No-Carrier-Added Astatination of N-Succinimidyl-3-(Tri-n-Butylstannyl) Benzoate (ATE) Via Electrophilic Destannylation¹.” Radiochimica Acta 47, no. 2–3 (January 1, 1989): 131–36. https://doi.org/10.1524/ract.1989.47.23.131.
    Full Text
  - Zalutsky, M. R., R. C. Bast, and R. C. Knapp. “Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen.” Int J Rad Appl Instrum B 16, no. 4 (1989): 405–11. https://doi.org/10.1016/0883-2897(89)90108-6.
    Full Text Link to Item
  - Zalutsky, M. R., R. C. Bast, and R. C. Knapp. “Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen.” Nuclear Medicine and Biology 16, no. 4 (January 1, 1989): 405–11.
  - Colapinto, E. V., P. A. Humphrey, M. R. Zalutsky, D. R. Groothuis, H. S. Friedman, N. de Tribolet, S. Carrel, and D. D. Bigner. “Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.” Cancer Res 48, no. 20 (October 15, 1988): 5701–7.
    Link to Item
  - GARG, P. K., H. FRIEDMAN, S. SLADE, D. D. BIGNER, and M. R. ZALUTSKY. “ASTATINE-211 LABELED MONOCLONAL-ANTIBODY - A POTENTIAL AGENT FOR RADIOIMMUNOTHERAPY.” European Journal of Nuclear Medicine 14, no. 5–6 (August 1, 1988): 245–245.
    Link to Item
  - Lee, Y., D. E. Bullard, P. A. Humphrey, E. V. Colapinto, H. S. Friedman, M. R. Zalutsky, R. E. Coleman, and D. D. Bigner. “Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.” Cancer Res 48, no. 10 (May 15, 1988): 2904–10.
    Link to Item
  - Zalutsky, M. R., and A. S. Narula. “Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate.” Cancer Res 48, no. 6 (March 15, 1988): 1446–50.
    Link to Item
  - Lee, Y. S., D. E. Bullard, M. R. Zalutsky, R. E. Coleman, C. J. Wikstrand, H. S. Friedman, E. V. Colapinto, and D. D. Bigner. “Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.” Cancer Res 48, no. 3 (February 1, 1988): 559–66.
    Link to Item
  - Colapinto, E. V., Y. S. Lee, P. A. Humphrey, M. R. Zalutsky, H. S. Friedman, D. E. Bullard, and D. D. Bigner. “The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.” Br J Neurosurg 2, no. 2 (1988): 179–91. https://doi.org/10.3109/02688698808992668.
    Full Text Link to Item
  - Hayes, D. F., M. A. Noska, D. W. Kufe, and M. R. Zalutsky. “Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells.” Int J Rad Appl Instrum B 15, no. 3 (1988): 235–41. https://doi.org/10.1016/0883-2897(88)90101-8.
    Full Text Link to Item
  - Lee, Y. S., D. E. Bullard, M. R. Zalutsky, R. E. Coleman, C. J. Wikstrand, H. S. Friedman, E. V. Colapinto, and D. Bigner. “Therapeutic Efficacy of Antiglioma Mesenchymal Extracellular Matrix 131I-Radiolabeled Murine Monoclonal Antibody in a Human Glioma Xenograft Model.” Cancer Research 48, no. 3 (January 1, 1988): 584–88.
  - Narula, A. S., and M. R. Zalutsky. “Synthesis of N-succinimidyl-2,4-dimethoxy-3-(tri-N-butylstannyl) benzoate via regio-specifically generated lithium 2,4-dimethoxy-3-lithiobenzoate.” Tetrahedron Letters 29, no. 35 (January 1, 1988): 4385–88. https://doi.org/10.1016/S0040-4039(00)80501-8.
    Full Text
  - Zalutsky, M. R., M. A. Noska, P. W. Gallagher, S. Shortkroff, and C. B. Sledge. “Use of liposomes as carriers for radiation synovectomy.” Int J Rad Appl Instrum B 15, no. 2 (1988): 151–56. https://doi.org/10.1016/0883-2897(88)90081-5.
    Full Text Link to Item
  - Zalutsky, M. R., M. A. Noska, P. W. Gallagher, S. Shortkroff, and C. B. Sledge. “Use of liposomes as carriers for radiation synovectomy.” Nuclear Medicine and Biology 15, no. 2 (January 1, 1988): 151–56.
  - Zalutsky, M. R., R. C. Knapp, and R. C. Bast. “Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody.” Int J Rad Appl Instrum B 15, no. 4 (1988): 431–37. https://doi.org/10.1016/0883-2897(88)90014-1.
    Full Text Link to Item
  - Zalutsky, M. R., R. C. Knapp, and R. C. Bast. “Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody.” Nuclear Medicine and Biology 15, no. 4 (January 1, 1988): 431–37.
  - Zalutsky, M. R., and A. S. Narula. “Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate.” International Journal of Radiation Applications and Instrumentation. Part A, Applied Radiation and Isotopes 39, no. 3 (January 1988): 227–32. https://doi.org/10.1016/0883-2889(88)90176-1.
    Full Text
  - Sledge, C. B., J. D. Zuckerman, S. Shortkroff, M. R. Zalutsky, P. Venkatesan, M. A. Snyder, and W. P. Barrett. “Synovectomy of the rheumatoid knee using intra-articular injection of dysprosium-165-ferric hydroxide macroaggregates.” J Bone Joint Surg Am 69, no. 7 (September 1987): 970–75.
    Link to Item
  - Zalutsky, M. R., M. de Sousa, P. Venkatesan, S. Shortkroff, J. Zuckerman, and C. Sledge. “Evaluation of indium-111 chloride as a radiopharmaceutical for joint imaging in a rabbit model of arthritis.” Invest Radiol 22, no. 9 (September 1987): 733–40. https://doi.org/10.1097/00004424-198709000-00007.
    Full Text Link to Item
  - Wikstrand, C. J., R. E. McLendon, S. Carrel, J. T. Kemshead, J. P. Mach, H. B. Coakham, N. de Tribolet, D. E. Bullard, M. R. Zalutsky, and D. D. Bigner. “Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model.” J Neuroimmunol 15, no. 1 (May 1987): 37–56. https://doi.org/10.1016/0165-5728(87)90005-1.
    Full Text Link to Item
  - Lee, Y. S., D. E. Bullard, C. J. Wikstrand, M. R. Zalutsky, L. H. Muhlbaier, and D. D. Bigner. “Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration.” Cancer Res 47, no. 7 (April 1, 1987): 1941–46.
    Link to Item
  - Zalutsky, M. R., M. A. Noska, and S. E. Seltzer. “Characterization of liposomes containing iodine-125-labeled radiographic contrast agents.” Invest Radiol 22, no. 2 (February 1987): 141–47. https://doi.org/10.1097/00004424-198702000-00010.
    Full Text Link to Item
  - Letvin, N. L., M. R. Zalutsky, J. M. Lambert, L. V. Chalifoux, L. M. Nadler, S. F. Schlossman, and H. L. Atkins. “Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys.” Int J Rad Appl Instrum B 14, no. 2 (1987): 99–105. https://doi.org/10.1016/0883-2897(87)90138-3.
    Full Text Link to Item
  - Zalutsky, M. R., and A. S. Narula. “A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine.” Int J Rad Appl Instrum A 38, no. 12 (1987): 1051–55. https://doi.org/10.1016/0883-2889(87)90069-4.
    Full Text Link to Item
  - Bullard, D. E., C. J. Wikstrand, P. A. Humphrey, Y. S. Lee, R. E. Coleman, M. Zalutsky, and D. D. Bigner. “Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs).” Nuklearmedizin 25, no. 6 (December 1986): 210–15.
    Link to Item
  - Zalutsky, M. R., M. A. Noska, and P. W. Gallagher. “Properties of multilamellar liposomes containing^99mTcO4^-: Effect of distearoylphosphatidylcholine to sphingomyelin ratio.” Nuclear Medicine and Biology 13, no. 3 (December 1, 1986): 269–76.
  - Hayes, D. F., M. R. Zalutsky, W. Kaplan, M. Noska, A. Thor, D. Colcher, and D. W. Kufe. “Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer.” Cancer Res 46, no. 6 (June 1986): 3157–63.
    Link to Item
  - Sledge, C. B., J. D. Zuckerman, M. R. Zalutsky, R. W. Atcher, S. Shortkroff, D. R. Lionberger, H. A. Rose, B. J. Hurson, P. A. Lankenner, and R. J. Anderson. “Treatment of rheumatoid synovitis of the knee with intraarticular injection of dysprosium 165-ferric hydroxide macroaggregates.” Arthritis Rheum 29, no. 2 (February 1986): 153–59. https://doi.org/10.1002/art.1780290201.
    Full Text Link to Item
  - Zalutsky, M. R., D. F. Hayes, and D. W. Kufe. “Radioiodination of DF3 antibody: Optimization using in vitro binding assays.” Journal of Labelled Compounds and Radiopharmaceuticals 23, no. 10–12 (January 1, 1986): 1301–3.
  - Zalutsky, M. R., M. A. Noska, and P. W. Gallagher. “Properties of multilamellar liposomes containing 99mTcO4-: effect of distearoylphosphatidylcholine to sphingomyelin ratio.” Int J Rad Appl Instrum B 13, no. 3 (1986): 269–76. https://doi.org/10.1016/0883-2897(86)90107-8.
    Full Text Link to Item
  - Zalutsky, M. R., P. P. Venkatesan, R. J. English, S. Shortkroff, C. B. Sledge, and S. J. Adelstein. “Radiation synovectomy with 165Dy-FHMA: lymph node uptake and radiation dosimetry calculations.” Int J Nucl Med Biol 12, no. 6 (1986): 457–65. https://doi.org/10.1016/s0047-0740(86)80008-0.
    Full Text Link to Item
  - Zalutsky, Michael R. “Radiohalogenation of monoclonal antibodies.” International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology 13, no. 6 (January 1986): 652–53. https://doi.org/10.1016/0883-2897(86)90050-4.
    Full Text
  - Zalutsky, M., P. Magistretti, P. Gallagher, and R. Ghidoni. “Radioiodinated ganglioside GM1: a potential tool for the investigation of ganglioside function in vivo.” Pharmacol Res Commun 17, no. 10 (October 1985): 897–912. https://doi.org/10.1016/0031-6989(85)90032-3.
    Full Text Link to Item
  - Kilbourn, M. R., and M. R. Zalutsky. “Research and clinical potential of receptor based radiopharmaceuticals.” J Nucl Med 26, no. 6 (June 1985): 655–62.
    Link to Item
  - De Sousa, M., A. M. Carroll, P. G. Herman, S. Kerr, J. Boulton, and M. R. Zalutsky. “Distribution and mechanism of uptake of 111InCl3 in a tumor model for lymph node metastases.” Int J Nucl Med Biol 12, no. 2 (1985): 89–96. https://doi.org/10.1016/0047-0740(85)90162-7.
    Full Text Link to Item
  - Zalutsky, M. R., D. Colcher, W. D. Kaplan, and D. W. Kufe. “Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors.” Int J Nucl Med Biol 12, no. 3 (1985): 227–33. https://doi.org/10.1016/0047-0740(85)90030-0.
    Full Text Link to Item
  - Carroll, A. M., M. Zalutsky, S. Schatten, A. Bhan, L. L. Perry, C. Sobotka, B. Benacerraf, and M. I. Greene. “Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen.” Clin Immunol Immunopathol 33, no. 2 (November 1984): 268–81. https://doi.org/10.1016/0090-1229(84)90081-3.
    Full Text Link to Item
  - Masuho, Y., M. Zalutsky, R. C. Knapp, and R. C. Bast. “Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas.” Cancer Res 44, no. 7 (July 1984): 2813–19.
    Link to Item
  - Bloomer, W. D., W. H. McLaughlin, R. M. Lambrecht, R. W. Atcher, S. Mirzadeh, J. L. Madara, R. A. Milius, M. R. Zalutsky, S. J. Adelstein, and A. P. Wolf. “211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y.” Int J Radiat Oncol Biol Phys 10, no. 3 (March 1984): 341–48. https://doi.org/10.1016/0360-3016(84)90052-x.
    Full Text Link to Item
  - Bloomer, W. D., W. H. McLaughlin, R. M. Lambrecht, R. W. Atcher, S. Mirzadeh, J. L. Madara, R. A. Milius, M. R. Zalutsky, S. J. Adelstein, and A. P. Wolf. “²¹¹At radiocolloid therapy: Further observations and comparison with radiocolloids of ³²P, ¹⁶⁵Dy, and ⁹⁰Y.” International Journal of Radiation Oncology, Biology, Physics 10, no. 3 (1984): 341–48.
  - Carroll, A. M., M. R. Zalutsky, B. Benacerraf, and M. I. Greene. “Monoclonal antibodies to tissue-associated antigens as antitumor reagents.” Surv Synth Pathol Res 3, no. 3 (1984): 189–200. https://doi.org/10.1159/000156925.
    Full Text Link to Item
  - Carroll, A. M., and M. R. Zalutsky. “Receptor-mediated radiopharmaceuticals.” Trends in Pharmacological Sciences 5, no. C (January 1, 1984): 57–60. https://doi.org/10.1016/0165-6147(84)90367-5.
    Full Text
  - Colcher, D., M. Zalutsky, W. Kaplan, D. Kufe, F. Austin, and J. Schlom. “Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody.” Cancer Res 43, no. 2 (February 1983): 736–42.
    Link to Item
  - Zalutsky, M. R., J. Wu, P. V. Harper, and T. Wickland. “Synthesis of ¹¹C-dl-tryptophan and its purification using high-pressure liquid chromatography.” The International Journal of Applied Radiation and Isotopes 32, no. 3 (January 1, 1981): 182–84. https://doi.org/10.1016/0020-708X(81)90114-9.
    Full Text
  - Kirchner, P. T., J. Ryan, M. Zalutsky, and P. V. Harper. “Positron emission tomography for the evaluation of pancreatic disease.” Semin Nucl Med 10, no. 4 (October 1980): 374–91. https://doi.org/10.1016/s0001-2998(80)80039-0.
    Full Text Link to Item
  - Friedman, A. M., J. Cheronis, and M. Zalutsky. “Preparation of ⁷⁷Br and ⁷⁶Br L-DOPA and 5-hydroxytryptophan analogues.” Journal of Labelled Compounds and Radiopharmaceuticals 16, no. 1 (January 1, 1979): 66–67.
  - Zalutsky, M., T. Wickland, J. Nickles, and P. V. Harper. “Nitrogen-13 nitrous oxide for cerebral imaging studies.” Journal of Nuclear Medicine 19, no. 6 (January 1, 1978): 700.
  - Zalutsky, M. R., A. M. Friedman, J. C. Sullivan, S. L. Ruby, and G. V. Rayudu. “Studies of tumor metabolism--II. Mössbauer spectroscopy of 57Co-bleomycin.” Int J Nucl Med Biol 4, no. 3–4 (December 1977): 216–18. https://doi.org/10.1016/0047-0740(77)90145-0.
    Full Text Link to Item
  - Zalutsky, M. R., A. M. Friedman, and F. C. Buckingham. “Synthesis of a non labile astatine protein conjugate.” Journal of Labelled Compounds and Radiopharmaceuticals 13, no. 2 (December 1, 1977): 181–82.
  - Zalutsky, M. R., G. V. Rayudu, and A. M. Friedman. “The biological behavior of tin following administration of nine 99mTc-Sn complexes.” Int J Nucl Med Biol 4, no. 3–4 (December 1977): 224–30. https://doi.org/10.1016/0047-0740(77)90147-4.
    Full Text Link to Item
  - Friedman, A. M., M. R. Zalutsky, W. Wung, F. Buckingham, G. H. Scherr, B. Wainer, R. L. Hunter, et al. “Preparation of a biologically stable and immunogenically competent astatinated protein.” International Journal of Nuclear Medicine and Biology 4, no. 3–4 (December 1977): 219–24. https://doi.org/10.1016/0047-0740(77)90146-2.
    Full Text
  - Zalutsky, M., J. C. Sullivan, A. M. Friedman, G. V. Rayudu, and E. Deutsch. “Organ distribution of 99mTc-labelled aminethiols.” Int J Nucl Med Biol 4, no. 1 (January 1977): 53–56. https://doi.org/10.1016/0047-0740(77)90042-0.
    Full Text Link to Item
  - Zalutsky, M. R., E. S. MacIas, and R. A. Meyer. “Structure of N=81 nuclei: Levels of Nd141 and Ce139 populated in beta decay.” Physical Review C 13, no. 4 (January 1, 1976): 1590–1600. https://doi.org/10.1103/PhysRevC.13.1590.
    Full Text
  - Zalutsky, M. R., E. S. Macias, and A. L. Catz. “Angular correlation between K and L x rays in tantalum.” Physical Review A 11, no. 1 (January 1, 1975): 75–78. https://doi.org/10.1103/PhysRevA.11.75.
    Full Text
  - Zalutsky, M. R., and E. S. MacIas. “Angular correlation of x rays: L-M cascades of plutonium.” Physical Review A 12, no. 2 (January 1, 1975): 526–30. https://doi.org/10.1103/PhysRevA.12.526.
    Full Text
  - Zalutsky, M. R., and E. S. MacIas. “Search for an anisotropy between Ll x rays and γ rays in the decay of Cm243.” Physical Review C 12, no. 3 (January 1, 1975): 1076–79. https://doi.org/10.1103/PhysRevC.12.1076.
    Full Text
  - Zalutsky, M. R., and E. S. Macias. “Decay of 5.8-min Pmm140 and 10-sec Pmg140 to levels of Nd140.” Physical Review C 12, no. 3 (January 1, 1975): 997–1002. https://doi.org/10.1103/PhysRevC.12.997.
    Full Text
  - Zalutsky, M. R., and E. S. Macias. “Comparison of techniques for the determination of the L2-L3X Coster-Kronig transition probability.” Physical Review A 11, no. 3 (January 1, 1975): 1093–96. https://doi.org/10.1103/PhysRevA.11.1093.
    Full Text
  - Zalutsky, M. R., and E. S. Macias. “Experimental determination of the L2-L3X Coster-Kronig transition probability in europium, plutonium, and curium.” Physical Review A 11, no. 1 (January 1, 1975): 71–74. https://doi.org/10.1103/PhysRevA.11.71.
    Full Text
  - Zalutsky, M. R., and E. S. Macias. “Measurement of the angular correlation between L-M X-ray cascades.” Physics Letters A 49, no. 4 (September 23, 1974): 285–86. https://doi.org/10.1016/0375-9601(74)90813-5.
    Full Text
  - Macias, E. S., R. E. Head, H. C. Hseuh, and M. R. Zalutsky. “On-line determination of transport time of a helium-jet system.” Nucl. Instrum. Methods (Netherlands) 122, no. 3 (1974): 365–68.
  - Macias, E. S., R. E. Head, H. C. Hseuh, and M. R. Zalutsky. “On-line determination of transport time of a helium-jet system.” Nuclear Instruments and Methods 122, no. C (January 1, 1974): 365–68. https://doi.org/10.1016/0029-554X(74)90501-1.
    Full Text
  - Macias, E. S., and M. R. Zalutsky. “K-L X-ray angular correlations in Cm, Pu and Eu.” Phys. Rev. A, Gen. Phys. (Usa) 9, no. 6 (1974): 2356–64. https://doi.org/10.1103/PhysRevA.9.2356.
    Full Text Link to Item
  - Zalutsky, M. R., and E. S. Macias. “Measurement of the angular correlation between L-M X-ray cascades.” Phys. Lett. a (Netherlands) 49A, no. 4 (n.d.): 285–86.
- Book Sections
  - Zalutsky, M. R. “Radiohalogens for radioimmunotherapy.” In Radioimmunotherapy of Cancer, 81–106, 2000.
- Conference Papers
  - Vaidyanathan, G. V., Z. Zhou, D. McDougald, T. Lahoutte, and M. R. Zalutsky. “Anti-HER2 Single Domain Antibody 2Rs15d Labeled with F-18 Using a Residualizing Label: Preliminary Evaluation.” In European Journal of Nuclear Medicine and Molecular Imaging, 43:S179–S179. SPRINGER, 2016.
    Link to Item
  - Vaidyanathan, G., D. McDougald, J. Choi, E. Koumarianou, M. Pruszynski, T. Osada, H. Lyerly, T. Lahoutte, and M. R. Zalutsky. “An Anti-HER2 Nanobody Labeled with 18F Using a Residualizing Label for Assessing HER2 Status.” In European Journal of Nuclear Medicine and Molecular Imaging, 42:S102–S102. SPRINGER, 2015.
    Link to Item
  - Schaal, Jeffrey Laurence, Wenge Liu, Ashutosh Chilkoti, Xinghai Li, Eric Mastria, and Michael R. Zalutsky. “Abstract 1809: Next-generation brachytherapy: a preclinical study of a thermally stabilized biopolymer gel for delivering intratumoral radionuclide therapy in a pancreatic tumor mouse model.” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-1809.
    Full Text
  - Barrott, Jared J., Aaron P. Smith, Takuya Osada, Nimmi Ramanujam, Michael R. Zalutsky, Kim Lyerly, and Timothy A. J. Haystead. “Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.” In Drug Metabolism, Transport, and Biodistribution. American Association for Cancer Research, 2013. https://doi.org/10.1158/1535-7163.targ-13-c86.
    Full Text
  - Sobolev, A. S., A. A. Rosenkranz, and M. R. Zalutsky. “Modular nanotransporters: a versatile platform for nuclear delivery of anti-cancer pharmaceuticals.” In Febs Journal, 280:376–376. WILEY-BLACKWELL, 2013.
    Link to Item
  - Liu, Wenge, Jonathan R. McDaniel, Xinghai Li, Jeffery Schaal, Jayanta Bhattacharyya, Michael R. Zalutsky, and Ashutosh Chilkoti. “Abstract 4341: A novel injectable polymer liquid that self-assembles into radioactive “seeds” for brachytherapy.” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-4341.
    Full Text
  - Zalutsky, M. R., and G. Vaidyanathan. “TARGETED ALPHA THERAPY.” In Radiotherapy and Oncology, 102:S195–S195. ELSEVIER IRELAND LTD, 2012.
    Link to Item
  - Vaidyanathan, Ganesan, Jianjun Li, Darell D. Bigner, and Michael R. Zalutsky. “TARGETED RADIOTHERAPY OF MEDULLOBLASTOMA USING SOMATOSTATIN RECEPTOR AVID RADIOLABELED PEPTIDES.” In Neuro Oncology, 13:I27–I27. OXFORD UNIV PRESS INC, 2011.
    Link to Item
  - Vaidyanathan, G., B. White, D. J. Affleck, D. McDougald, and M. R. Zalutsky. “Radioiodinated O6-Benzylguanine Analogues Containing an Azido Function.” In European Journal of Nuclear Medicine and Molecular Imaging, 37:S265–S265. SPRINGER, 2010.
    Link to Item
  - Chin, B. B., R. W. Storms, K. Base, C. Lascola, T. Haystead, M. R. Zalutsky, and G. Vaidyanathan. “[I-125] iodoquine uptake in tumor cell lines with high ALDH expression.” In European Journal of Nuclear Medicine and Molecular Imaging, 34:S222–S222. SPRINGER, 2007.
    Link to Item
  - Pruszynski, M., A. Bilewicz, and M. R. Zalutsky. “Synthesis of Rh[16aneS4] At-211 and Ir[16aneS4] At-211 complexes - new prosthetic groups for labelling with astatine.” In European Journal of Nuclear Medicine and Molecular Imaging, 34:S210–S210. SPRINGER, 2007.
    Link to Item
  - Dreher, Matthew R., Wenge Liu, Michael R. Zalutsky, Mark W. Dewhirst, and Ashutosh Chilkoti. “Targeted drug delivery to solid tumors using thermally responsive elastin-like polypeptide macromolecular drug carriers.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.
    Link to Item
  - Boskovitz, A., C. Pegram, K. Peixoto, M. R. Zalutsky, and D. D. Bigner. “Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas.” In Neuro Oncology, 7:370–370. DUKE UNIV PRESS, 2005.
    Link to Item
  - Vaidyanathan, G., K. L. Alston, P. C. Welsh, and M. R. Zalutsky. “Enhanced cellular retention of an internalizing anti-EGFRvIII monoclonal antibody radioiodinated using LYS5-[*I]iodobenzoyl Gly(1)-maleimido GEEEK ([*I]IB-Mal-D-GEEEK), a prosthetic group containing negatively charged D-glutamates.” In Neuro Oncology, 7:386–386. DUKE UNIV PRESS, 2005.
    Link to Item
  - Vaidyanathan, G., K. Base, and M. R. Zalutsky. “0(6)-{4-(3-[F-18]fluoropropyl)-benzyl}-2 '-deoxyguanosine ([F-18]FPBdG) - Synthesis and evaluation of a potential DNA repair protein 0(6)-alkyguanine-DNA alkyltransferase (AGT) imaging agent.” In Abstracts of Papers of the American Chemical Society, 229:U182–U182. AMER CHEMICAL SOC, 2005.
    Link to Item
  - Boskovitz, A., G. Vaidyanathan, G. E. Archer, H. Ochiai, T. Okamura, J. H. Sampson, D. D. Bigner, and M. R. Zalutsky. “Medulloblastoma neoplastic meningitis targeted radiotherapy with intrathecal alpha-emitter At-211-labeled thymidine analogue.” In Neuro Oncology, 6:403–403. DUKE UNIV PRESS, 2004.
    Link to Item
  - Kuan, C. T., C. J. Wikstrand, T. S. Davis, M. R. Zalutsky, and D. D. Bigner. “Monoclonal antibodies (MABS) against somatostatin receptor 2A (SSTR2A) as potential medulloblastoma therapeutic reagents.” In Neuro Oncology, 6:409–409. DUKE UNIV PRESS, 2004.
    Link to Item
  - Vaidyanathan, G., A. Boskovitz, H. S. Friedman, D. J. Affleck, and M. R. Zalutsky. “Somatostatin targeted radiotherapeuiccs for medulloblastoma.” In Neuro Oncology, 6:416–416. DUKE UNIV PRESS, 2004.
    Link to Item
  - Boyd, M., K. W. Tan, S. C. Ross, J. Dorrens, M. R. Zalutsky, and R. J. Mairs. “Investigation of cell kill in a targeted radiotherapy/gene therapy strategy utilising radiation induced biological bystander effects.” In Journal of Gene Medicine, 6:S30–S30. JOHN WILEY & SONS LTD, 2004.
    Link to Item
  - Boyd, M., R. J. Mairs, S. Ross, J. Dorrens, and M. R. Zalutsky. “A tumour specific targeted radiotherapy/gene therapy for the treatment of malignant disease.” In Journal of Gene Medicine, 6:S33–34. JOHN WILEY & SONS LTD, 2004.
    Link to Item
  - Cosimo, E., M. Boyd, A. McCluskey, T. Robson, M. R. Zalutsky, and R. J. Mairs. “Enhancement of targeted radiotherapy in neuroblastoma: a novel gene therapy approach.” In Journal of Gene Medicine, 6:S27–S27. JOHN WILEY & SONS LTD, 2004.
    Link to Item
  - Akabani, G., D. A. Rizzieri, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, et al. “Phase I trial study of [131]I-labeled chimeric 81C6 mAb for the treatment of patients with non-Hodgkin's lymphoma.” In European Journal of Nuclear Medicine and Molecular Imaging, 31:S222–S222. SPRINGER, 2004.
    Link to Item
  - Boyd, M., E. Cosimo, A. G. McCluskey, A. M. Clark, T. Robson, H. O. McCarthy, M. R. Zalutsky, and R. J. Maits. “Enhancement of targeted radiotehrapy in neuroblastoma: A novel gene therapy approach.” In British Journal of Cancer, 91:S19–S19. NATURE PUBLISHING GROUP, 2004.
    Link to Item
  - Boskovitz, A., G. Akabani, X. G. Zhao, K. Alston, and M. R. Zalutsky. “Astatine-211 labeled Herceptin: An alpha-particle emitting radiotherapeutic.” In Clinical Cancer Research, 9:6189S-6189S. AMER ASSOC CANCER RESEARCH, 2003.
    Link to Item
  - Zalutsky, M. R. “Targeted radiotherapy of brain tumours.” In British Journal of Cancer, 88:S6–S6. NATURE PUBLISHING GROUP, 2003.
    Link to Item
  - Vaidyanathan, G., D. J. Affleck, and M. R. Zalutsky. “N-succinimidyl 3-[211AT]astato-4-guanidinomethylbenzoate: An acylation agent for labeling internalizing antibodies with alpha-particle emitting (211)AT.” In Abstracts of Papers of the American Chemical Society, 225:U265–U265. AMER CHEMICAL SOC, 2003.
    Link to Item
  - Wilbur, D. S., D. K. Hamlin, M. K. Chyan, C. Foulon, M. R. Zalutsky, T. Wedge, and M. F. Hawthorne. “Optimizing methods for labeling biomolecules with astatine-211.” In Abstracts of Papers of the American Chemical Society, 225:U264–65. AMER CHEMICAL SOC, 2003.
    Link to Item
  - Zalutsky, M. R., O. Pozzi, X. G. Zhao, and K. L. Alston. “Evaluation of astatine-211 labeled targeted radiotherapeutics.” In Abstracts of Papers of the American Chemical Society, 225:U264–U264. AMER CHEMICAL SOC, 2003.
    Link to Item
  - SMELLIE, W. J. B., C. J. DEAN, N. P. M. SACKS, M. R. ZALUTSKY, P. K. GARG, P. CARNOCHAN, and S. A. ECCLES. “RADIOIMMUNOTHERAPY OF BREAST-CANCER XENOGRAFTS WITH MONOCLONAL-ANTIBODY ICR12 AGAINST C-ERBB2 P185 - COMPARISON OF IODOGEN AND N-SUCCINIMIDYL 4-METHYL-3-(TRI-N-BUTYLSTANNYL)BENZOATE RADIOIODINATION METHODS.” In Cancer Research, 55:S5842–46. AMER ASSOC CANCER RESEARCH, 1995.
    Link to Item
  - GARG, P. K., C. R. BERRY, S. GARG, T. R. DEGRADO, M. R. ZALUTSKY, and R. E. COLEMAN. “PARA-[F-18]FLUOROBENZYLGUANIDINE ([F-18]PFBG) - FURTHER EVALUATION OF A POTENTIAL PET RADIOTRACER IN DOGS.” In Proceedings of the Xvi International Cancer Congress Free Papers and Posters, Tomes 1 4, edited by R. S. Rao, M. G. Deo, L. D. Sanghvi, and I. Mittra, 113–18. MONDUZZI EDITORE, 1994.
    Link to Item
  - VAIDYANATHAN, G., D. J. AFFLECK, S. A. SLADE, P. WELSH, and M. R. ZALUTSKY. “NO-CARRIER-ADDED 4-FLUORO-3-IODOBENZYLGUANIDINE LABELED WITH I-131 ([I-131]FIBG) AND F-18 ([F-18]FIBG - POTENTIAL MIBG ANALOGS FOR PET IMAGING AND THERAPY OF NEUROENDOCRINE TUMORS.” In Proceedings of the Xvi International Cancer Congress Free Papers and Posters, Tomes 1 4, edited by R. S. Rao, M. G. Deo, L. D. Sanghvi, and I. Mittra, 3013–17. MONDUZZI EDITORE, 1994.
    Link to Item
  - Vaidyanathan, G., D. K. Strickland, D. A. Affleck, P. Welsh, and M. R. Zalutsky. “Meta-[²¹¹At]astatobenzylguanidine: Further validation of in vitro and in vivo uptake mechanisms.” In Journal of Labelled Compounds and Radiopharmaceuticals, 35:589–91, 1994.
  - ZALUTSKY, M. R. “RADIONUCLIDE THERAPY - A REVIEW.” In Hadrontherapy in Oncology, edited by U. Amaldi and B. Larsson, 1077:664–76. ELSEVIER SCIENCE PUBL B V, 1994.
    Link to Item
  - FRIEDMAN, A. M., J. CHERONIS, M. ZALUTSKY, M. COOPER, P. HOFFMAN, A. HELLER, D. ISRAELSTAM, et al. “PREPARATION OF BR-77 AND BR-76 L-DOPA AND 5-HYDROXYTRYPTOPHAN ANALOGS.” In Journal of Labelled Compounds & Radiopharmaceuticals, 16:66–67, 1979.
    Link to Item
  - ZALUTSKY, M., T. WICKLAND, J. NICKLES, and P. V. HARPER. “N-13 NITROUS-OXIDE FOR CEREBRAL IMAGING STUDIES.” In Journal of Nuclear Medicine, 19:700–700, 1978.
    Link to Item
Teaching & Mentoring
Recent Courses

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Awards & Honors

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers

Recent Courses